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Abstract 
Pneumonia remains the leading cause of illness and death in children less than 5 years of age 
in low-and-middle-income countries. Both bacteria and viruses are major causes of 
pneumonia in children. The disease burden attributed to the different respiratory pathogens 
varies with season and between regions. Knowledge of the relative importance of each agent 
is essential for adequate case management as well as prevention strategies, such as 
development of vaccines. This thesis focuses on respiratory viruses as causes of pneumonia. 
The basis for the present thesis is: 1) a cross-sectional study of 2,219 children with 
community-acquired pneumonia as defined under the Integrated Management of Childhood 
Illness (IMCI) program in the World Health Organization and 2) a case-control study of 680 
pneumonia cases and 680 matched controls. Study subjects were included at a field clinic in 
Bhaktapur, Nepal. A nasopharyngeal aspirate was collected from each child at inclusion and 
examined for seven respiratory viruses using a commercial multiplex reverse transcription 
polymerase chain reaction (PCR) assay. The aim of the large cross-sectional study was to 
obtain information on the frequency of these seven common respiratory viruses and their 
seasonal distribution over a three-year period. Moreover, the study was designed to obtain 
information on clinical characteristics and outcomes of the pneumonia episodes and how the 
individual respiratory viruses were associated with these factors. The case-control study was 
undertaken to measure the degree to which the individual viruses were associated with IMCI 
defined pneumonia. 
We identified at least one virus in a large proportion (40%) of the children with pneumonia. 
Respiratory syncytial virus (RSV), influenza A, and parainfluenza virus (PIV) type 3 were 
most frequently detected among the seven viruses in the three-year study. The epidemics of 
infection with individual respiratory viruses contributed substantially to the observed 
pneumonia epidemics. RSV occurred in yearly epidemics in relation to the rainy season or 
during the winter. We also found that RSV infection was associated with signs of severe 
illness; the children infected with RSV more frequently had severe pneumonia and, among 
infants, low oxygen saturation, compared to children who were RSV negative. Among cases 
with non-severe pneumonia, the children with RSV infection had longer time to recovery 
and increased risk of treatment failure compared to the other children. The case-control 
study revealed that all the seven viruses were associated with pneumonia but that the 
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strength of this association varied. RSV, PIV type 3 and influenza A were most strongly 
associated with pneumonia. 
Our findings indicate that these viruses are important causes of pneumonia in young children 
in Bhaktapur. Although influenza A and PIV type 3, like RSV, were among the most 
common viruses and were strongly associated with pneumonia, RSV was by far the most 
frequently detected virus over the three-year period and children infected with RSV had the 
most severe clinical presentations and outcomes. This supports the notion that development 
of a safe and effective RSV vaccine should be a priority for prevention of pneumonia in 
young children in low-and-middle-income countries. 
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1. Introduction 
The global burden of acute respiratory infection 
Acute respiratory infection (ARI) is one of the leading causes of illness and death in children 
under five years of age (under-5s). According to World Health Organization (WHO) 
estimates, nearly 2 million under-5s die from ARI every year, corresponding to about 19% 
of all deaths in this age group (1). Pneumonia and bronchiolitis are considered to be leading 
contributors to the global burden of ARI in young children and responsible for the greater 
part of these deaths, of which the vast majority occurs in the developing world. The WHO 
algorithm for classification of ARI identifies children with acute lower respiratory tract 
infection (ALRI) as being in need of antibiotic treatment, acknowledging that a substantial 
part of the infections are actually viral. In this thesis, I use the term pneumonia as defined 
under WHO’s Integrated Management of Childhood Illness (IMCI) program, which captures 
the clinical entities of both pneumonia and bronchiolitis and is sometimes referred to as 
“clinical pneumonia” (2). Aspects related to the challenges inherent in this classification of 
pneumonia are discussed in further detail below (“Diagnosing pneumonia”). Hereafter the 
terms pneumonia and ALRI will be used interchangeably. 
The incidence of pneumonia in under-5s in industrialized countries is estimated at 0.05 
episodes per child-year. In contrast, the incidence in low-and-middle-income countries 
(LMICs) is approximately 0.3 episodes per child-year, which translates into more than 150 
million new episodes annually (3). The regions with the highest incidence are South-East 
Asia and sub-Saharan Africa. The incidence varies with the prevalence of several risk 
factors; including malnutrition, low birth weight, non-exclusive breastfeeding, indoor air 
pollution, and crowding (4). Incidence also varies with age and is higher in infants than in 
toddlers, i.e. young children 12 months old (3). 
Etiological agents in childhood pneumonia 
A variety of infectious agents cause pneumonia, but Streptococcus pneumoniae 
(pneumococcus), Haemophilus influenzae, Staphylococcus aureus and respiratory syncytial 
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virus (RSV) are considered to be the most important respiratory pathogens in areas without 
adequate pneumococcal and H. influenza type b (Hib) vaccine coverage, i.e. in most of the 
developing world. Other important respiratory viruses are influenza A and B, parainfluenza 
virus (PIV) type 1-3, human metapneumovirus (hMPV) and adenovirus. Until recent 
increases in measles vaccine coverage, measles still accounted for a substantial number of 
pneumonia deaths in children (5). In general, the true burden of the various organisms 
causing pneumonia is inadequately documented in LMICs due to lack of surveillance 
systems and diagnostic facilities (6). 
Bacterial etiology 
Etiology studies in the 1980s and 90s found pneumococcus to be the most common cause of 
severe pneumonia in LMICs, followed by H. influenzae and S. aureus (7-11). These studies 
were based on lung or pleural puncture combined with blood culture and included only a 
small number of children. Vaccine probe studies (12-17) have more recently been used to 
estimate disease burden attributable to pneumococcus and Hib (18, 19). It is estimated that 
nearly 14 million episodes of pneumococcal pneumonia and 8 million episodes of Hib 
pneumonia occur in under-5s annually, and pneumococcus alone cause around 700,000 
deaths from pneumonia in this age group (18, 19). Estimates based on the proportion of 
radiographically confirmed pneumonia prevented in vaccine probe studies and supported by 
lung aspiration studies indicate that pneumococcus cause 17% to 37% of pneumonia cases 
among under-5s (20). The corresponding proportion for Hib is estimated at 0-31% (20). 
Other important bacterial organisms with varying occurrence are Staphylococcus aureus, 
which may cause severe, necrotizing pneumonia with complicated effusion and rapid 
progression, non-type-b H. influenzae, and Klebsiella pneumoniae (3, 20, 21). Non-typhoid 
Salmonella species have been associated with non-severe pneumonia in malaria-endemic 
tropical regions of Africa, but its etiological role in pneumonia is still controversial (3). 
Several other gram-negative bacteria as well as atypical organisms such as Mycoplasma 
pneumoniae and Chlamydophila pneumoniae also cause pneumonia, but are not believed to 
be among the most common causes in the under-5 age group (21). Additionally, 
Mycobacterium tuberculosis has been identified in a proportion of acute pneumonia (7) and 
still continues to be an important cause of severe illness and death in children (6), especially 
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in areas with high HIV infection prevalence (22-25). Pneumonia due to opportunistic fungal 
infections with Pneumocystis jirovecii is also frequent in HIV endemic areas (26). 
Viral etiology 
Among the common respiratory viruses, which cause a wide range of illnesses from mild 
infections of the upper respiratory tract to pneumonia, RSV undoubtedly cause most severe 
illness and is responsible for a large proportion of hospitalizations in infants and young 
children attributable to these viruses in industrialized countries (27, 28). Hospitalization for 
RSV-associated illness in under-5s in the United States is three-fold more common than for 
influenza and PIVs (29-31). Globally, an estimated 34 million new episodes of RSV 
associated ALRI occurred in under-5s in 2005, of which 3.4 million required hospital 
admission and near 200,000 resulted in death (32). However, accurate information on the 
RSV disease burden in LMICs is lacking. Few population-based estimates of RSV incidence 
rates in LMICs are available (33-36), but existing data suggest that the incidence is high both 
in developing and in industrialized countries (29, 32). With limited and variable access to 
and quality of health care services in LMICs, morbidity and mortality are likely to be 
substantially higher (32, 37). The proportion of pneumonia cases that is caused by RSV in 
LMICs was estimated at a median of 20% (5
th
 to 95
th
 percentile 1 to 53) using data from 
children included in 87 studies (37). 
PIVs, particularly type 1, 2 and 3, are second to RSV in causing severe viral lower 
respiratory infection in children (38). Parainfluenza viruses involve the lower airways less 
frequently and result in fewer hospitalizations than RSV (27, 31). The difference between 
hospitalization rates for RSV and PIV is particularly striking for the first six month of life 
(27). Hospitalization rates for RSV have been estimated to be 3 per 1000 children/year for 
the age group below 5 years and 17 per 1000 for those below 6 months (29), while the 
corresponding rates for PIV are 1 and 3 per 1000 (31). PIVs have been associated with 
pneumonia in LMICs (39), but the proportion of cases with PIV type 1, PIV type 2 and PIV 
type 3 in hospital- and community-based studies is not determined. 
Seasonal influenza causes a significant number of acute respiratory infections, including 
pneumonia, among children (21). The disease burden has been largely under-recognized, 
especially in the community (30). In the Unites States, annual rates of outpatient visits 
attributable to influenza were reported to be around 95 fold higher than hospitalization rates 
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for children under 5 years, while the highest rates of hospitalization (4.5 per 1000 children) 
were reported for those below 6 months of age (30), similar to for RSV and parainfluenza 
(29, 31). The role of influenza in contributing to pneumonia has been uncertain, particularly 
in LMICs, but recent data from Bangladesh indicate that it could be substantial (40). In 
Hong Kong (41), population-based estimated hospitalization rates for influenza exceeded 
those reported in the United States (30). Respiratory viruses also play an important role in 
the pathogenesis of pneumonia by predisposing to bacterial infections, a feature especially 
associated with influenza virus (42). 
In 2001, hMPV was detected in the Netherlands and is together with RSV a member of the 
subfamily Pneumovirinae within the Paramyxoviridae family (43). The virus is now 
recognized as an important causative agent of ARI in children, both in the community and in 
hospitalized cases (44). It seems to have a worldwide distribution, being detected in a large 
number of locations (45). The rate of hospitalization for hMPV infection has been found to 
be lower than for RSV infections but higher than that observed for influenza and 
parainfluenza viruses (46, 47). High incidence rates for hMPV-ALRI hospitalization are 
reported in South Africa and Hong Kong (48, 49). Available data show that hMPV account 
for approximately 5-8% of ARI hospitalizations (44, 50-52) and 2-6% of community cases 
of ARI in children below 5 years of age in industrialized countries (44, 50, 53). Hospital-
based studies of children 5 years in LMICs have shown similar occurrence (54-57), but 
very few studies report on hMPV pneumonia in the community (58). 
Seasonality of respiratory viral infections 
Infections with these respiratory viruses exhibit distinct seasonal patterns in most temperate 
regions. Typically, RSV and influenza cause annual recurrent well-defined epidemics during 
the cold months (37, 59, 60). The activity of hMPV has been shown to be greatest in winter 
and spring in the northern hemisphere (44) and autumn through spring in the southern 
hemisphere (48, 53, 61), but data are still somewhat limited as year-round surveillance has 
not been extensively undertaken. In initial reports, the hMPV incidence varied substantially 
from year to year (62). There are now reports suggesting a biennial epidemic pattern of early 
and late hMPV occurrence in several European countries (59, 63, 64). PIV type 3 infections 
occur year round with outbreaks usually occurring in spring, while type 1 and 2 demonstrate 
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a biennial pattern with epidemics in the fall or early winter, sometimes in alternate years (65-
67). 
Although the seasonal variations of RSV and influenza infections have been extensively 
studied in various LMICs, especially for RSV, it is difficult to outline a clear pattern. A 
review by Weber and coworkers (39) revealed that RSV infections peaked during the cold 
months in temperate regions in the southern hemisphere, seemingly independent of rainfall. 
In sub-tropical and tropical locations with seasonal rainfall, RSV tended to occur in relation 
to the rainy season, however, in locations closer to the equator with perennial rainfall, RSV 
activity was almost continuous and peaks of infection varied (39). Influenza is also reported 
to be detectable throughout the year in tropical and sub-tropical regions with less predictable 
timing of outbreaks, although there are reports of a biannual pattern of outbreaks with 
considerable activity between epidemic periods (60). The peak hMPV season is reported to 
be during late winter to spring in Bangladesh (58) and India (54), while outbreaks have been 
observed in spring and autumn in South Korea (68) and in spring and summer in Hong Kong 
(49), but observation periods for these studies have only been 1-2 years. In a three-year 
study in South Africa, hMPV was seen in yearly epidemics, peaking during autumn and 
winter (48). There are few comprehensive reports on seasonality of PIVs from developing 
regions. Most studies have a short observation time and many studies did not distinguish 
between the different PIV types (69, 70). Seasonal observations in Singapore and Taiwan 
were largely similar to those in temperate regions described above (71, 72). 
Clinical and epidemiological aspects of respiratory viral 
infections 
RSV causes a wide spectrum of respiratory infections from rhinitis and otitis media to severe 
infections of the lower respiratory tract. The virus is the major cause of bronchiolitis in 
infancy and a significant cause of pneumonia during the first few years of life (73). Between 
25 to 33% of primary RSV infections involve the lower airways (74), but this proportion is 
lower in reinfections and with increasing age (75). Infants are at highest risk of developing 
severe manifestations of the infection, especially before 6 months of age (75). Severe disease 
typically presents with fever, cough, expiratory wheeze, dyspnea and cyanosis (74). Spread 
of RSV from contaminated nasal secretions occurs via large respiratory droplets (76), which 
requires close person-to-person contact or contact with contaminated surface for 
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transmission. The virus persists on environmental surfaces for hours and is thus a frequent 
cause of nosocomial infections, especially in pediatric wards (6, 76). Primary infection is 
rarely asymptomatic and reinfections are frequent. In a prospective study in the United 
States, around two-thirds of children were infected during their first year of life, and by the 
age of two, nearly all children had experienced one infection and nearly half had been 
infected twice (75). Reinfections occur in all ages as immunity to RSV infection is 
incomplete and short-lived (77), but disease severity wanes with age (67). However, RSV 
may cause severe infections in immunocompromized adults and elderly people (78). 
Hospitalization for RSV bronchiolitis has been associated with subsequent asthma and 
wheezing in children (79, 80), but atopy and wheezing have also been shown to be risk 
factors for RSV hospitalization in young children (81). The majority of children who get 
severe RSV disease are otherwise healthy, but premature infants, infants with congenital 
heart disease, cystic fibrosis, bronchopulmonary dysplasia, or immunodeficiency are at 
particular high risk of severe illness (28, 82-84). Several other important risk factors for 
severe RSV illness related to the environment and the host have been identified, including 
male sex, age <6 months, birth in the first half of the RSV season, crowded living 
conditions, siblings, lack of breastfeeding, and day care exposure (85). Level of passively 
acquired maternal antibody to RSV could be an underlying factor in age of acquisition (86). 
A recent study of RSV burden in the United States found that only prematurity and young 
age were independent risk factors for hospitalization (29). 
Influenza infection in children mainly manifests as febrile illness with respiratory symptoms, 
but can also cause severe respiratory illness, particularly in individuals with underlying 
cardiopulmonary conditions (6). High fever, rhinitis and cough are common features of 
influenza illness in children (40, 87-90), while adults frequently experience general malaise, 
headache, and myalgia as well. In young children influenza resembles other severe 
respiratory tract infections causing pneumonia, bronchiolitis, croup, otitis media, and, more 
rarely, febrile convulsions (74). Virus is transmitted via aerosols and droplets from 
respiratory secretions generated through coughing and sneezing, or by contaminated hands 
(6). Children experience the highest attack rates during seasonal epidemics (91), as they 
typically shed high amounts of viruses during infection and thus have an important role in 
the transmission in the community (92), while individuals aged 65 years and older 
experience most serious illness, complications and death from influenza (93). Among 
children, those younger than 2 years of age are most susceptible to severe consequences of 
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influenza infection (88, 90, 91) and estimates of hospitalization rates due to influenza are 
similar to those of adults at high risk (94, 95). Studies report no difference in clinical 
symptoms or signs between illness episodes caused by type A and B, but some have found 
children hospitalized with influenza A infection to be younger (89, 90, 96). 
Like RSV, parainfluenza viruses cause infections restricted to the respiratory tract (74). 
While PIV type 1, 2 and 3 are the principal causes of croup, type 3 is also known to cause 
pneumonia and bronchiolitis in young children, typically in infants (67). The subglottal 
swelling in croup results in a barking cough, tachypena, tachycardia and suprasternal 
retraction (74). PIVs usually cause mild cold-like upper respiratory infection (URI) or 
pharyngitis, but approximately 15-25% of infections spread to the lower respiratory tract 
(66, 74). PIV type 3 is considered second to RSV in causing severe infections in infants, 
both with peak incidence of hospitalization before 6 months of age (29, 31). The virus is 
transmitted by respiratory droplets and person-to-person contact (74). Most children are 
infected with PIV type 3 by two years of age and with types 1 and 2 by five (67). Like for 
RSV, reinfections occur throughout life, as acquired immunity is short-lived (97). There are 
indications that croup is relatively less frequent in LMICs (38). Caucasian children have for 
instance been found to have higher incidence of croup compared to African-American (98). 
The clinical manifestations of hMPV are similar to those of RSV (44, 99) and sometimes 
those of influenza (45). However, a number of studies report hMPV to cause less severe 
illness, more frequently manifest as pneumonia than bronchiolitis and infect slightly older 
children than those infected with RSV (100-107). Infections with hMPV have also been 
found to cause respiratory disease of similar severity as RSV infections (47). Seroprevalence 
surveys have shown that virtually all children are infected with hMPV by the age of 5 (43). 
The virus cause infection in all age groups, but has its greatest effect in children; those <2 
years have the highest incidence and are at the highest risk of serious infections (44, 108). 
Pre-term infants also seem prone to severe disease (99). Adults usually suffer from relatively 
mild common cold-like respiratory symptoms (109), but like RSV and influenza virus 
infections, hMPV infections may also cause severe illness in the elderly and in patients with 
underlying disease (44, 109, 110). Several studies suggest that hMPV, like RSV, may be 
associated with episodes of acute wheezing and asthma exacerbations in children (44). Risk 
factors for severe hMPV disease and frequency of reinfections have not been extensively 
studied (111-114). 
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Control of pneumonia 
Interventions targeting risk factors for pneumonia are required for primary prevention, 
whereas case management aims at reducing disease severity and case fatality. Both strategies 
are needed to reduce pneumonia mortality. The WHO ARI standard case management 
approach developed in the 1980s focuses on early detection and treatment with appropriate 
antibiotics (115) and has been the cornerstone of pneumonia control in low-income 
countries. The program was later incorporated into the Integrated Management of Childhood 
Illness (IMCI) guidelines (116). Community-based implementation of this case management 
strategy has greatly reduced overall and pneumonia mortality in young children (117), but 
implementation is lagging behind in many high-incidence countries and therefore has 
substantial potential for improvement (118). However, increasing antimicrobial resistance of 
pathogens causing pneumonia (25, 119) demonstrates the need for additional strategies. 
There are also areas for improvement in facility-based treatment. Hypoxia is associated with 
increased risk of mortality from pneumonia (120) and proper assessment and treatment of 
hypoxia has been shown to substantially reduce case fatality (121). The use of pulse 
oximetry is far more accurate than clinical signs in detecting hypoxia (122). Unfortunately, 
oximetry and oxygen therapy are unavailable in many developing country settings. 
Vaccination against the important respiratory pathogens is effective in the prevention of 
childhood pneumonia and leads to a reduction in mortality; immunization against pertussis, 
measles, and pneumococcal infection being striking examples (5). While Hib and 
pneumococcal conjugate vaccines are licensed and recommended by WHO for inclusion in 
national programs (123, 124), LMICs can ill afford them. Special initiatives by the Global 
Alliance for Vaccines and Immunization (GAVI) may increase coverage (5). Vaccines 
against RSV and PIV type 3 are currently being developed (5), despite earlier setbacks, 
especially for RSV vaccines (38). 
Malnutrition is an underlying factor in more than half of all under-5 deaths (4) and is 
strongly associated with an increased risk of dying from pneumonia (125). In fact, about a 
quarter of pneumonia deaths in LMICs are attributable to underweight or stunting alone 
(126). Promotion of exclusive breastfeeding, especially in the first month of life, and 
improving zinc nutriture are other potentially effective interventions in the prevention of 
pneumonia (126). 
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In 2007, WHO and UNICEF initiated a Global Action Plan for Pneumonia (GAPP) to 
increase awareness of pneumonia as a major killer of children and to develop a unified and 
equitable approach towards pneumonia control (127). In order to increase child survival, 
countries should focus on four areas that offer the best prospects for pneumonia control, 
namely vaccines, case management, nutrition and environment (128). Vaccines against 
measles, pertussis, pneumococcus and Hib, effective case management at both community 
and health facility levels, improvement of nutrition through promotion of exclusive 
breastfeeding and improving zinc nutriture, and reducing the prevalence of low birth weight 
are identified as key strategies for pneumonia control with the potential to substantially 
reduce pneumonia illness and death in under-5s (129). Environmental interventions, such as 
improvement of indoor air quality through cleaner fuels and better stoves, may prevent 
pneumonia and should be encouraged (129). In addition, prevention and management of 
HIV infection is also perceived as a major area that needs to be addressed to prevent 
pneumonia (129). 
Diagnosing pneumonia 
The diagnosis of true bacterial pneumonia in children remains a challenge, despite the 
frequency and severity of this condition. The reference standard for diagnosing pneumonia is 
an aspirate from the lower respiratory tract obtained by lung puncture or bronchoscopy 
(130). As a non-invasive proxy, radiography is considered a pragmatic reference standard for 
the diagnosis of pneumonia, but due to variability in interpretations by radiologists, this 
method also has its clear limitations (131). To improve the agreement of radiological 
categorization of pneumonia with alveolar consolidations in children, WHO established 
standardized criteria for interpretation of chest radiographs (132). This approach is limited 
by the fact that the classical radiologic feature of alveolar consolidation is not produced by 
all bacterial pneumonia episodes and may also be caused by non-bacterial pathogens (133). 
Moreover, chest x-ray may be negative in the early course of pneumonia and radiographic 
changes brought about by pneumonia may persist for weeks after recovery. Auscultatory 
findings, such as crepitations and bronchial breath sounds, used by doctors in the clinical 
assessment are largely subjective and have proven difficult to standardize (130).  
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Identifying cases of bacterial pneumonia is crucial to better target antibiotic treatment. This 
is especially a challenge in LMICs where limited resources imply that comprehensive 
individual investigation may not be feasible. The WHO ARI case management approach 
aims to facilitate and standardize clinical decision-making in resource-limited settings (134) 
and classifies pneumonia in order to inform case management. In contrast to the 
conventional diagnosis of pneumonia that uses a combination of clinical signs, chest x-ray or 
laboratory investigations, the WHO algorithm for classification of ARI is based on simple 
clinical signs only. These signs, which trained health workers can recognize accurately, have 
been validated and found to be sensitive and specific indicators of pneumonia (135). Thus, 
WHO defines pneumonia as an acute episode with fast breathing or lower chest indrawing in 
children with cough or difficult breathing. This approach identifies most children that 
potentially suffer from pneumonia and thereby require antibiotics, but in fact also 
encompasses those with bronchiolitis and a number of those suffering from reactive airways 
disease with superimposed respiratory infection (134). Global estimates of morbidity and 
mortality for clinical pneumonia are largely based on this definition (2). 
Determining the etiology of pneumonia  
Important rationale for pneumonia etiology research in LMICs is to establish evidence-based 
treatment guidelines (136) and direct the development of preventive strategies. Determining 
the etiology of childhood pneumonia has been attempted for decades, but has been hampered 
by the lack of sufficiently sensitive and specific tests. Most importantly, representative 
specimen from the lower respiratory tract is difficult to obtain. Children do not easily 
produce expectorate for examination, which even in adults is of questionable relevance for 
identifying the causative agents of pneumonia due to possible contamination by upper 
respiratory flora (137). Lung puncture is an invasive procedure and limited to those with a 
distinct area of consolidation on chest x-ray, thus, studies in LMICs based on such data are 
limited (138). Isolation of bacteria from blood of a child with signs of lung infection is 
highly specific for bacterial pneumonia but carries low sensitivity because the majority of 
cases are not bacteremic (139). The value of serology is often dependent on the availability 
of paired serum samples to assess any antibody titer increase, as well as the time of serum 
collection in relation to the onset of illness (140, 141). Some pathogens are difficult to 
culture and require advanced laboratory facilities that are not available in many hospitals. 
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Moreover, many widely employed methods for detection of pathogens causing pneumonia 
are flawed, leaving no adequate gold standard for testing performance of new diagnostic 
methods, such as nucleic acid detection. Rapid tests of bacterial etiology by antigen 
detection in urine are not able to differentiate between colonization and infection with 
bacteria (142). Since children in LMICs frequently are carriers of pneumococcus and Hib 
(143-145) (146), the tests have low specificity in children. It is not possible to clinically 
distinguish between bacterial and viral pneumonia in young children, and biomarkers, such 
as serum concentrations of acute phase proteins e.g. C-reactive protein (CRP) and 
procalcitonin, add little to the diagnostic accuracy (147-149). Vaccine probe studies are 
perhaps the best available means to determine the proportion of pneumonia attributable to a 
specific pathogen, but notably only estimate the role of the vaccine-type strains of a 
pathogen on a population level (150). There is also a possibility of serotype-replacement 
disease, as seen among Alaska native children (151). 
The ability of the common epidemic respiratory viruses to cause lower respiratory tract 
infection is well established, also for the relatively recently discovered hMPV. As opposed 
to several bacteria, respiratory viruses do not colonize the upper respiratory tract, but rather 
replicates in mucosal epithelial cells in the upper airways (152). Virus isolation by tissue 
culture of nasopharyngeal specimens depends on the presence of viable virus and has 
traditionally been considered the gold standard for diagnosing respiratory viral infection 
(153). It has generally been assumed that a viral pathogen detected in upper respiratory tract 
secretions during ALRI is the cause of the illness (154). There are however, some problems 
inherent in this view. All the major viruses that cause pneumonia may cause a spectrum of 
clinical illness from inapparent infection of the upper airways to severe infection of the 
lower respiratory tract. In fact, acute respiratory infections initiate in the upper respiratory 
tract epithelium and in some cases descend to the lower respiratory tract. In general, 
infection is much more common in the upper than in the lower respiratory tract and on 
average, young children typically experience 5 episodes of URI yearly (155). A virus may be 
detected before the onset of symptoms and sometimes for a period after recovery, which 
means that a child may test positive for a respiratory virus for several weeks of the year. 
Thus, a virus present in a specimen from upper respiratory tract during pneumonia could be 
either causal or incidental, questioning its causal role in individual cases and making 
epidemiological estimates of causality across individuals prone to exaggeration. 
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The wide application of molecular methods in routine diagnostics of ARI has improved 
sensitivity compared to conventional methods, such as tissue culture and direct fluorescent 
antibody assays (153, 156-158). Moreover, molecular diagnostics have facilitated 
simultaneous detection of multiple pathogens in a single specimen and reduced analysis 
time. Polymerase chain reaction (PCR) assays have been developed for detection of 
rhinovirus and for newly discovered viruses such as hMPV, human bocavirus (hBoV) and 
subtypes of coronavirus. Combined with the use of comprehensive diagnostic testing 
protocols including a wide array of pathogens, this has resulted in an increase in the 
proportion of specimen from patients that test positive for any respiratory pathogen. 
However, there is a penalty to this increased sensitivity. An increase in the proportion of test 
positive specimen also from asymptomatic individuals (159), especially in young children 
(160) and the frequent detection of multiple pathogens in single specimens, particularly in 
studies utilizing multiple diagnostic methods including sensitive PCR assays to detect 
respiratory agents (59, 161, 162) have complicated the interpretation of positive PCR results. 
These issues have raised concern regarding the clinical relevance of detecting certain viral 
pathogens in upper airways secretion and highlight the problem of ascribing the cause to 
individual agents. Consequently, it is essential to determine the proportion of virus positive 
nasopharyngeal specimens in a control group before making assumptions about causality. 
Most studies of viral etiology have failed to do so. 
Focus of the thesis 
Data on etiology and clinical presentation of childhood pneumonia are important for 
planning and assessment of pneumonia control strategies (163). In addition, data on etiology 
enable more accurate evaluation of the impact of new interventions, such as the introduction 
of vaccines (152). Such data are lacking for many LMICs, including Nepal. The focus of this 
thesis is to examine the epidemiological and clinical importance, in terms of frequency, 
seasonality and severity, of 7 respiratory RNA viruses in young Nepalese children with 
pneumonia in a community-based setting. The viruses were identified in nasopharyngeal 
aspirates (NPAs) using a validated (158, 164-166) commercial multiplex reverse 
transcription PCR assay. Using data from a cross-sectional study and a case-control study 
embedded therein, we measured the proportion of pneumonias with and calculated 
pathogenicity odds ratios (ORs) for these 7 viruses. These ORs measure the degree to which 
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the viruses are associated with pneumonia. Because we do not believe reverse causality is a 
relevant problem in this context, this is likely to be the best available measure of causality.  
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2. Objectives 
Overall objective 
To assess the role of RNA viruses in community-acquired pneumonia in young Nepalese 
children. 
Specific objectives  
In young Nepalese children; 
1. Identify common viral pathogens in community-acquired pneumonia over a three-
year period (Paper I); 
2. Describe the seasonality of common viral pathogens in community-acquired 
pneumonia over a three-year period (Paper I); 
3. Describe the clinical presentation, severity and course of viral community-acquired 
pneumonia (Paper II); 
4. Measure the association between the presence of respiratory viruses in 
nasopharyngeal aspirates and pneumonia (Paper III). 
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3. Methods 
Nepal demographics 
Nepal is a landlocked country in South Asia bordered by China and India. It is commonly 
divided into three major areas that run east-west: the arid Mountain Region with the 
Himalayan Range in the north, the central Hill Region that includes the Kathmandu Valley, 
and the Terai Region, which refers to the southern fertile and densely populated lowland 
plains. The climatic zones corresponds to the altitude and range from tropical to arctic. The 
proximity to the Bay of Bengal makes Nepal influenced by the Indian monsoon in the 
summer.  
The population exceeded 25 millions in 2006 (167). Nearly one quarter of the population 
lives below the poverty line (1 USD per day) (168). Labor migration to the Gulf, India and 
Malaysia is widespread. The overall adult literacy rate is 56.5% (169), but there are great 
disparities between genders and across regions (167). In 2001, only 14% of the population 
lived in urban areas (170), but this may have increased during the ten-year long Maoist led 
violent insurgency that ended in 2006. The infant mortality rate (per 1000 live births) has 
declined the last 15 years from 79 (1991-1995) to 48 (2001-2005) (167) and life expectancy 
at birth is around 66 years (169). Undernutrition is common, especially among children. 
About half of the children below 5 years were stunted and nearly 40% were under-weight in 
2006 (167). The Expanded Program on Immunization (EPI) began in 1979 and official 
figures indicate that overall coverage for all basic vaccines (BCG, measles, and three doses 
each of DPT and polio vaccine) had reached 83% in 2006 (167). 
Study area and population 
The studies presented were undertaken in Bhaktapur district (Figure 1) in the eastern part of 
the Kathmandu Valley (27°N, 85°E). The valley is situated at an altitude 1,300-1,350 meters 
above sea level and has a sub-tropical, temperate climate with four distinct seasons; pre-
monsoon/spring (March-May), monsoon/summer (June-September), post-monsoon/autumn 
(October-November) and winter (December-February) (171). Temperatures may rise to 
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35°C in summer, while minimum temperatures can fall to 0°C in winter. The valley is the 
most densely populated area in the country. 
Bhaktapur town is the district headquarters with a population of about 80,000. The 
municipality is divided into 17 administrative ‘wadas’ or neighborhoods. The Newars form 
the major ethnic group in the area and a large proportion is involved in subsistence farming. 
Migrant minority groups, such as the Lama and the Tamang, are more frequently engaged 
working in numerous carpet or brick factories, which makes them more dependent on 
purchasing food items and hence vulnerable to fluctuations of the prices in the market. 
Undernutrition, mainly manifest as stunting, and anemia, is common among children below 
5 years of age (172). The vaccine coverage is >90% for all vaccines included in the national 
EPI (173).  
 
Figure 1. Map of Nepal with details of Bhaktapur district with municipality boundaries and surrounding 
village development committees (VDCs). 
Prior to study start, we undertook a baseline census of children below three years of age 
living in households in the 17 wadas in Bhaktapur municipality. This census, which covered 
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8,398 households, showed that 41% of families with young children owned some 
agricultural land, while 22% owned domestic animals. Most of the households had access to 
piped drinking water (97%) and toilet with central drainage (88%). About half of the 
families owned their own accommodation (52%), while 46% lived in only one room. 
Although winters are cold and houses not isolated, heating of rooms is not common. 
Cooking is mainly done indoors and kerosene was used by 51%. 
Fieldwork  
One cross-sectional study and one case-control study form the basis of this thesis. A display 
of the field studies and methods in relation to the papers is given below (Table 1). 
Table 1. Study design, period, topic and main analyses of the field studies presented in the respective 
papers. 
 
 
 
 
 
Recruitment area and strategy 
The baseline census formed the basis for the surveillance system that was set up and 
maintained throughout the study period (Figure 2). We generated a list of all children below 
three years of age using the data from the census and regularly updated the list by identifying 
newborn babies and excluding children who had completed 36 months of age, moved away 
from the area or left the cohort for other reasons.  The children in this open cohort were 
subject to monthly active surveillance and received a card that entitled them to free basic 
Paper Study type Study period Topic Main analyses
I Cross-sectional study 29 June 2004 to 30 June 2007 Identification of common 1) Descriptive statistics
of children with WHO- respiratory viruses and
defined pneumonia their seasonality
(n=2,219)
II Cross-sectional study 29 June 2004 to 30 June 2007 Clinical presentation, 1) Logistic regression
of children with WHO- severity and outcome of 2) Cox regression
defined pneumonia pneumonia episode
(n=2,219)
III Matched case-control 25 March 2006 to 9 July 2007 Comparison of virus 1) Conditional logistic
study of children with frequency in children with regression
and without WHO- and without pneumonia
defined pneumonia
(n=1360)
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health services at the project facility. At first encounter, the fieldworker collected detailed 
information about the household and the individual child. At the monthly visits, he or she 
obtained information, mainly from the mother, on symptoms of respiratory and diarrheal 
illness during the last seven days and referred children with symptoms of illness to the study 
clinic. In the area outside the municipality, no regular surveillance was undertaken and 
household information was obtained only when a child was included in the study.  
 
 
 
 
 
 
Figure 2. Time points for initiation and ending of the baseline census, the surveillance of children <3 
years of age, and the clinical trial with inclusion periods for cases and controls in the virus studies. The 
virus studies that form the basis for the current thesis were embedded in the clinical trial. 
For the cross-sectional study (paper I and II), the participants were recruited mainly from the 
municipality of Bhaktapur, i.e. from the open cohort of children that were under active 
surveillance. However, we also included eligible children with pneumonia from the 
surrounding district if brought to the study clinic. A total of 1,899 (85.6%) of the 2,219 cases 
were recruited from within the municipality, while the remaining came from the adjacent 
village development committees in the district. In the case-control study (paper III), both 
cases and controls were recruited solely from within the municipality of Bhaktapur. 
The project staffed an outpatient department at Siddhi Memorial Hospital in the outskirts of 
Bhaktapur and families could bring their children for free treatment at our clinic for common 
childhood illnesses. In addition, the project ran a 10-bed pediatric ward with 24-hour service 
where mainly children with severe pneumonia were admitted. 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
2007
Census
Surveillance of children <3 years of age in Bhaktapur municipality
Inclusion of pneumonia cases for viral testing
Clinical trial assessing the effect of zinc for pneumonia
Inclusion of controls
2003 2004 2005 2006
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Recruitment of cases, case definition and exclusion criteria 
Children aged 2-35 months who came to our study clinic were screened for fast breathing or 
lower chest wall indrawing (LCI) and classified according to the standard WHO algorithm 
for ARI (174). Pneumonia was defined as cough or difficult breathing combined with fast 
breathing, i.e. 50 breaths/min for children 2-11 months old, and 40 breaths/min for 
children 12 months old. Severe pneumonia was defined as cough or difficult breathing 
combined with LCI. Children with auscultatory wheeze were given 2 doses of 2.5 mg 
nebulized salbutamol administered 15 minutes apart followed by reassessment after 30 
minutes. A child was included only if he or she had fast breathing or LCI at reassessment. 
Cases with very severe pneumonia/disease, i.e. cough or difficult breathing with stridor 
when calm or any general danger signs (inability to drink/breastfeed, persistent vomiting, 
convulsions, lethargy or unconsciousness) were not included, but instead referred to a 
tertiary level hospital after initial treatment. Cases with other severe illness, documented 
tuberculosis, congenital heart disease, dysentery, severe anemia (defined as hemoglobin <7 
mg/L), or severe malnutrition (defined as <70% National Health Care Surveys median 
weight for height) were not included in the study. Those with a history of cough for more 
than 14 days or who had received antibiotics within the last 48 hours were excluded. 
Children could not participate in the cross-sectional study again (paper I and II) until after 6 
months because of restrictions imposed by the clinical trial protocol (175). Children included 
in the case-control study (paper III) could be enrolled as a case or as a control in the study 
again only after 2 months. The exclusion criteria for cases also applied to the controls, 
except that hemoglobin was not routinely measured in control children. 
Paper I and II 
We included 2,230 cases of pneumonia among 1,909 children from June 29, 2004 to June 
30, 2007. Only for five days in September 2004 were we not able to include children due to 
lack of NPA collection equipment. The children were, after obtaining informed parental 
consent, enrolled in a clinical trial assessing the effect of zinc as adjuvant therapy in children 
with pneumonia (175). All included children were randomized to receive either zinc (10 mg 
for children aged 2–11 mo, 20 mg for children aged 12 mo) or placebo daily for 14 days 
adjuvant to antibiotics. 
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Paper III 
We included children in the case-control study from March 25, 2006 in parallel with the 
undertaking of the zinc supplementation trial. The last case was included on June 30 and the 
last control on July 9, 2007. Among the 680 cases in the case-control study, 570 were also 
included in the zinc-pneumonia trial, while 110 cases were not because less than 6 months 
had lapsed from the previous enrolment in the trial. Hence, not all the laboratory 
investigations, such as CRP, were available at baseline for the cases that did not enroll in the 
zinc trial. A “grace period” of two months was set to ensure that cases were not included 
twice for the same episode. 
Selection of controls (paper III) 
Controls were matched by age (in months) of the case. One control was randomly selected 
for each case from the list of children under surveillance that was updated monthly. After 
inclusion of a case, a fieldworker visited the home of a potential control child on the same or 
the following day. If parents consented to the child’s participation, he or she was referred to 
the study clinic to be examined for eligibility as a control. If the child did not come to the 
clinic after two home visits, or was not found or not eligible for other reasons, another 
randomly selected age-matched child was approached. 
Case management 
Children with non-severe pneumonia received oral antibiotic treatment with cotrimoxazole 
for five days according to the WHO’s standard case management guidelines for pneumonia 
(12) and were examined daily by a fieldworker until recovery. The day of recovery was 
defined as the first of two consecutive days with a normal respiratory rate for age as assessed 
by the fieldworker. The fieldworker referred the child to the clinic if he or she still had fast 
breathing at 72 hours after inclusion. If the study physician confirmed pneumonia, treatment 
was changed to amoxycillin for 5 days. Treatment failure was defined as a change of 
antibiotic or hospitalization for pneumonia within the first three days after inclusion. Cases 
of severe pneumonia were hospitalized and received parenteral benzylpenicillin as first line 
treatment. Children with oxygen saturation (SpO2) <90% received oxygen treatment. 
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Data collection 
The fieldworkers involved in data collection were trained in standard case management 
according to the IMCI strategy (176) for one week, facilitated by Nepalese pediatricians and 
investigators from the study group in Nepal, who also trained and supervised doctors in 
study procedures.  
The child’s respiratory rate (RR) was assessed according to WHO guidelines (177), counting 
twice for one minute using a UNICEF timer. If only one of the counts were in the fast 
breathing range, counting was repeated and the two counts that were in the same category 
were recorded. The lower of the two counts was used in the analyses. We attempted to count 
the RR in children that were either awake and quiet or sleeping, as breastfeeding may 
increase the RR in some children and make assessment of LCI difficult. The majority of 
children were assessed while awake and quiet (96%), a small number while sleeping (3%), 
and very few while breastfeeding (<1%). 
Arterial SpO2 was measured either on a finger or a toe with a pulse oxymeter (Siemens 
MicrO2, Siemens Medical Systems Inc, Danvers, MA, USA) using a pediatric sensor 
(Nellcor, Pleasanton, CA, USA). It was recorded twice one minute apart after stabilization of 
the reading for one minute. The higher of the two measurements was used in the analyses. 
To determine the normal values for SpO2 in children living in Kathmandu (at approximately 
1,350 meters above sea level), we conducted a reference study among 425 healthy children 
aged 2 to 35 months attending the vaccination clinic in Kanti Children’s Hospital in 
Kathmandu. SpO2 was measured twice as described above. According to Duke and 
coworkers (121), the lowest value for normal oxygen saturation in children can be defined as 
the mean SpO2 minus 2 standard deviations (SD). In our group of healthy children, the mean 
(SD) was 95.9% (1.50), which gives a lower limit of SpO2 of 93% among normal children. 
Based on these data, we used SpO2 <93% for defining hypoxia in the three papers, but we 
also present the proportions of children with SpO2 <90%; this is the WHO threshold for 
oxygen administration (178). 
We registered the location of the children’s residence in Bhaktapur, i.e. children under 
surveillance (including the controls) as well as all included pneumonia cases, using handheld 
global positioning system (GPS) devises (eTrex, Garmin Ltd., Olathe, KS, USA). The 
geographical location of the houses was visualized using a GPS-based computerized plot 
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(Google Earth Pro) and was utilized to map the distribution of viral infections in the 
community over time. 
Collection, processing and storage of nasopharyngeal aspirates 
NPA specimens were obtained using a sterile, disposable suction catheter (Pennine 
Healthcare Ltd., Derbyshire, UK) with a suction trap (trachea suction set, 
Unomedical a/s, Birkerød, Denmark) connected to a foot pump (Ambu® Uni-Suction 
Pump, Ambu A/S, Ballerup, Denmark). The catheter was inserted through the child’s 
nostril to a distance equivalent of that from the nostril to the earlobe [21]. Suction 
was applied for minimum of ten seconds with maximum negative pressure of 200 
mm Hg. Secretion remaining in the catheter after suction was recovered by rinsing 2-
3 ml virus transport medium (DiagnoStick®, Department of Microbiology, 
University Hospital of North Norway, Tromsø, Norway) through the catheter into the 
suction trap. The trap was then disconnected and sealed. In March 2006, we changed 
transport medium to Universal Transport Medium (UTM) System (Copan 
Diagnostics Inc., Corona, CA) because the in-house product DiagnoStick® was no 
longer available. The new transport medium had the advantage of tolerating storage 
temperatures from 2-30°C before use, while the DiagnoStick® had to be kept frozen 
before use when stored for longer periods of time. 
The specimens were refrigerated at 2-8°C following collection at the field clinic and 
transported on ice every working day to the main laboratory in Kathmandu, where 
they were vortexed and divided in three equal aliquots in sterile vials (CryoTubes™, 
Nunc AS, Roskilde, Denmark). The aliquots analyzed in Nepal were either frozen at 
–70°C or kept refrigerated at 2-8°C before analysis (paper I and II). Two aliquots 
were immediately frozen at –70°C and transported to Norway on dry ice and again 
stored at –70°C for quality control purpose. The specimens for the case-control study 
(paper III) were all refrigerated at 2-8°C before analysis (mean number of days of 
storage was approximately 10 days (range 0-37), median 6 days [IQR 3-12]). The 
storage conditions were identical for case and control specimens. 
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Comparative study of different storage temperatures 
There is concern regarding degradation of viral RNA by storing specimens at temperatures 
of 2-8°C as compared to -70°C. We therefore undertook a separate study comparing results 
between samples refrigerated at 2-8°C for up to four months (i.e. 125 days) and samples 
frozen at -70°C immediately after processing. Assuming the frozen storage as gold standard, 
this comparative study showed that the sensitivity for samples refrigerated for up to four 
months was 93%. Moreover, the sensitivity did not differ substantially between samples 
refrigerated for periods of 2 months, 3 months and 4 months (data not shown). The 
specificity was 96% in the refrigerated samples compared to the frozen samples. It is not 
likely that specificity, as opposed to sensitivity, would be affected by prolonged storage at 2-
8°C. 
Setting up and running the virus laboratory in Kathmandu 
The project hired a bus to shuttle fieldworkers from Kathmandu to Bhaktapur in the morning 
and back again in the evening five days a week. This bus also carried the NPA specimens 
from the field clinic to the project office in Kathmandu. Samples were received, processed 
and frozen by one of the project laboratory staff. Initially we used a -70°C freezer that was 
available in the research laboratory to store our samples, but to increase the freezer capacity 
we purchased a -86°C ultra-low temperature freezer that was shipped from Norway to Nepal. 
This freezer broke down within the first year and had to be replaced by a second freezer also 
shipped from Norway because there were no possibilities for repairing the broken freezer in 
Nepal. Despite these challenges, none of the specimens suffered accidental thawing. 
The dry ice for transportation of NPA aliquots to Norway had to be ordered from New 
Delhi, India, through a local dealer in Nepal and was shipped to Kathmandu by air. We had a 
special bag made in Nepal for shipment purpose for transportation to Norway. There were 
always substantial amounts of dry ice remaining at arrival, indicating that temperatures 
during transport had been below -40°C. 
The Department of Microbiology at Tribhuvan University Teaching Hospital provided the 3-
room facility that we needed to set up a PCR laboratory. A lot of laboratory equipment and 
consumables were hand-carried from Norway to Nepal. The reagents for the PCR assays 
were imported directly from USA. This was divided into three major shipments over the 
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three-year period due to limited shelf life of the reagents. We also ordered pipette tips in 
bulk from France. Nepal charges a high tax on imported goods. This motivated an 
application for import tax exemption for our research material, which was a rather lengthy 
process that had to be repeated for every shipment. The body at the university that dealt with 
these applications was not operational for a longer period of time during the political unrest 
in the spring of 2006 when King Gyanendra was forced by the democracy movement to 
renounce his sovereign power. This delayed import of essential reagents for the laboratory 
for several months. Due to a general shortage of electricity in Nepal, the power supply is not 
continuous in Kathmandu at certain times of the year. The authorities scheduled local “load 
shedding”, and the power could be discontinued for up to ~30 hours a week. To avoid 
interrupted power supply in our laboratory, we installed a back-up battery that would last for 
the required number of hours of the scheduled power cut, which rarely exceeded 4 hours. 
However, this battery was too small to serve as a back up for the freezers, which 
occasionally were without power. Therefore, we monitored the freezer temperature, which 
was never recorded to be above -40°C at any time. 
Competence/capacity building 
The Department of Microbiology and Infection Control at the University Hospital of North 
Norway (UNN) in Tromsø supported us in the planning and set up of the laboratory. Håkon 
Haaheim, a UNN staff, and myself (MM) went for a one-week training in the facilities of 
Prodesse in Waukeshaw, WI, USA in September 2004. Unfortunately, the two main 
Nepalese laboratory staffs, Biswa Nath Sharma and Govinda Gurung, were not granted a US 
visa for this trip. They received training in PCR analyses at the virus laboratory in the 
Department of Microbiology at All India Institute of Medical Sciences (AIIMS) under 
supervision of Professor Shobha Broor for ten days in April 2005 together with me. Håkon 
Haaheim travelled to Nepal in August 2005 to assist us in setting up the lab and to start the 
PCR analyses. The following year Ann Helen Helmersen from UNN visited Nepal for two 
weeks to provide assistance in making analysis procedures more efficient. This, and the 
introduction of multi-channel pipettes and PCR strips instead of individual PCR vials, 
resulted in a 3-fold increase in analysis capacity. In 2006 two of the Nepalese laboratory 
staff had a one-week stay at the Department of Microbiology and Infection Control at UNN 
for additional training. 
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Virus identification 
One aliquot of each specimen was tested at our research laboratory in Nepal for RSV, 
influenza A and B, PIV type 1, 2 and 3, and hMPV using a commercially available multiplex 
reverse transcription PCR assay (Hexaplex Plus, Prodesse Inc., Waukeshaw, WI) with 
minor modifications of the manufacturer’s instructions (179) and previous descriptions 
(166). In brief, nucleic acids were extracted from 360 l of NPA using a nucleic acid (NA) 
extraction kit (Roche High Pure Viral Nucleic Acid Kit, F. Hoffman-La Roche Ltd., Basel, 
Switzerland) according to the manufacturer’s instructions. Each run of the assay included a 
positive RNA control and a negative control (virus transport medium), starting at NA 
isolation. Specimens and negative controls were individually spiked with 40 l of internal 
control during NA isolation to identify any inhibition. Reverse transcription with random 
hexamers and multiplex PCR were performed according to the Hexaplex Plus protocol using 
GeneAmp
®
 PCR System 2700 (ABI, Applied Biosystems, Foster City, CA, USA). The PCR 
supermix contained seven pairs of forward and backward primers flanking unique sequences 
of the seven viruses (the hemagglutinin neuraminidase gene of PIV type 1, 2 and 3, the 
matrix protein gene of influenza A, the NS1 and NS2 genes of influenza B, the NS1 and 
NS2 genes of RSV and the nucleocapsid gene of hMPV). After amplification, the PCR 
products were purified using Qiagen QIAquick PCR Purification Kit (QIAGEN Inc., 
Valencia, CA, USA) and analyzed by enzyme hybridization assay (EHA) (166), measuring 
the optical density at 450 nm (OD450) using a micro-plate reader (Stat Fax
®
 2100, Awareness 
Technology Inc., Palm City, FL, USA). The EHA was mainly run directly with individual 
probes discriminating between the different types of PIV and influenza. However, the EHA 
was during some periods run with pooled probes for PIV and influenza and then 
discriminated in a second EHA if the pooled probe yielded a positive result. Definitions of 
cut-off values and interpretation of PCR results were as described in paper III.  
Three hundred and twenty-four NPA aliquots were stored beyond 3 months at 2-8°C before 
analysis in Nepal. Of these, we reanalyzed the 133 that yielded a negative result, now using 
the aliquot that had been frozen at –70°C and transported on dry ice to Norway. This was 
done at the Department of Microbiology and Infection Control, UNN, Tromsø, Norway, 
using the Hexaplex Plus assay and an automated extraction platform (NucliSens® 
easyMAG, bioMérieux, Durham, NC). Nucleic acids were extracted from 400 l of sample, 
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negative and positive processing controls and amplification control using the extraction 
principle with magnetic particles of this platform. 
Statistical analyses 
Statistical analyses were performed using Stata/MP version 10.1 for Macintosh (Stata 
corporation, College Station, TX, USA). Anthropometric measures were expressed as Z-
scores, which were generated using the WHO Child Growth Standards 2005 (180). 
Statistical significance was defined as a P-value <0.05. 
In paper I and II, the 95% confidence intervals (CI) for proportions were calculated with 
binominal exact confidence interval using the “ci” command. Relative proportions were 
calculated using the “binreg” command. We used Cox proportional hazard models to 
estimate the association between viral status and duration of the non-severe pneumonia 
episodes. The odds ratio for treatment failure in non-severe cases was calculated using 
logistic regression. In the multiple regression models where each virus was used as the 
exposure variable we included age, breastfeeding status, whether the child belonged to the 
zinc or placebo arm of the trial, as well as presence of the seven different viruses. We also 
performed these analyses using high CRP (as an indirect marker of bacterial infection) as the 
exposure variable. In these latter analyses we included viral status (positive or negative) in 
the model instead of each of the seven viruses. Of the children included in these analysis, 
274 were enrolled twice and 18 thrice. We used the “cluster” option in Stata to adjust the P-
values and the confidence intervals of our estimates for repeated enrollments and thus 
allowed for possible dependence of observations in a child that was included more than 
once. 
Meteorological data for the Kathmandu airport weather station (located approximately 10 
km from Bhaktapur) were obtained from Department of Hydrology and Meteorology, 
Ministry of Environment, Science and Technology, Kathmandu, Nepal. Mean daily values 
for relative humidity and temperature were calculated as the average of two daily 
measurements (relative humidity at 8.45 AM and 5.45 PM, and maximum and minimum 
temperature). We estimated the Spearman rank order correlation coefficient to describe the 
association between the monthly number of infections with each virus and meteorological 
factors. 
  
Viral pneumonia in children 
43 
Proportions in the baseline table of paper III were compared using logistic regression. In an 
unmatched design, the pathogenicity odds ratio (OR) for each virus is the odds of detecting a 
pathogen-positive specimen from a child with pneumonia divided by the odds of detecting a 
pathogen-positive specimen from a control child. To take the matching into account, we 
estimated the pathogenicity using conditional logistic regression to calculate the matched 
OR (MOR). Because we sampled each control concurrently, i.e. shortly after the 
corresponding case had been identified, this OR is a direct estimate rather than a biased 
approximation of the incidence rate ratio for the given pathogen (181). These analyses 
included 1,360 specimens from 1,059 children of whom 808 were enrolled once, 210 twice, 
33 three times, 7 four times, and one child five times. We used the “cluster” option in Stata 
to take repeated enrollments and thus possible dependence of observations in children that 
were included more than once into account when calculating the confidence intervals and P-
values of these pathogenicity estimates. This adjustment only marginally affected the 
precision of the presented estimates. We sought to identify possible confounders, such as the 
presence of other viruses, sex, breastfeeding status, stunting, wasting, and whether the child 
had been delivered in a hospital, using unconditional logistic regression including age 
categories as factors. We also explored whether the MORs were different in children below 
and above 6 months of age for the two most common viruses. The P-values for such possible 
interactions were obtained from the unconditional models. 
Ethical issues 
The protocol for the study descried in paper I and II had ethical clearance from the Research 
Ethics Committee of the Institute of Medicine at Tribhuvan University in Kathmandu, Nepal 
as well as from the Regional Committee for Medical and Health Research Ethics (REK) of 
Western Norway (REK project no. 129.03). The protocol for the case-control study in paper 
III was approved by the Research Ethics Committee at Tribhuvan University, Nepal. Ethical 
approval was not sought in Norway, which was according to the Norwegian national 
guidelines at the time of application (2005). The storage of NPA specimens in Norway have 
been registered and approved by the Norwegian National Biobank Register, Norwegian 
Institute of Public Health (research biobank no 1832). 
Informed consent for participation was obtained from the guardian of the child, usually one 
of the parents. A witnessed verbal informed consent was obtained from those who were 
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illiterate and a register of witnesses was kept at the field site. Children below three years of 
age received treatment for common childhood illnesses free of charge and this was not 
limited to study participants. Participants were informed that withdrawal of consent did not 
affect health care services offered by the project. 
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4. Results 
The geographical location of houses of children <3 years old that underwent monthly 
surveillance and the pneumonia cases enrolled in the clinical trial are depicted in figure 3. 
 
 
Figure 3. Google Earth map images of the eastern part of the Kathmandu Valley including Bhaktapur 
municipality showing the geographical distribution of households of children <3 years old under 
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monthly surveillance (white squares) and children with pneumonia (blue squares) enrolled in the clinical 
trial. 
Subject characteristics 
Cross-sectional study (paper I & II) 
For this three-year study, we included 2,230 pneumonia cases. We excluded 11 cases from 
the analyses because of inhibition of the PCR. Of the remaining 2,219 cases, 56.9% were 
boys and 45.8% were infants (i.e. 2 to 11 months). The overall mean (SD) age  of the study 
children was 13.4 (8.3) months but this was substantially lower among the children with 
severe pneumonia (8.6 [7.4] months). There were also more (62.6%) boys in the group with 
severe pneumonia. The majority (87.7%) of children were still breastfed at the time of 
inclusion in the study. Mean birth weight was 2,86 kg in the 1,585 children where this 
information was available, and 224 (14%) had low birth weight (<2,5 kg). Hospital delivery 
was reported in 1,718 (77.5%). Wasting was more frequently seen among cases with severe 
pneumonia than among non-severe cases (6.1% vs 3.6%), while the proportions of stunting 
were very similar (22% vs 24%). About a quarter of mothers reported not being able to read 
or write, while this was much less common among fathers (5%). Sixty-six percent of 
mothers did not work outside their home and almost half of the fathers (48.6%) were daily 
wage earners (i.e. work contracted on a day-to-day basis). 
Case-control study (paper III) 
The background characteristics of the cases in the case-control study did not differ from the 
larger population of cases described above with regard to age, sex, breastfeeding, birth 
weight, anthropometrical measures, or socio-economic variables. The controls were more 
often born in hospital than the cases (89% vs 81%), but their birth weights were nearly 
identical. A larger proportion of the cases were wasted and stunted compared to controls, but 
the differences were not substantial and the total numbers of children with wasting and 
stunting were small. There were a slightly higher proportion of controls that came from 
families owning agricultural land, belonged to the Newar caste, or lived in an extended 
family as compared to the cases (Table 1 in paper III). Other background characteristics 
were evenly distributed between the two groups. 
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Virus analyses 
An overview of the main findings are shown in table 2. 
Frequency of respiratory viral infections (paper I) 
We detected at least one virus in 887 (40%) of the 2,219 pneumonia cases from June 2004 to 
July 2007. More than one virus was detected in only 29 (3.3%) of the positive specimens. 
RSV was the most common of the seven viruses being identified in 334 (15.1%) cases. 
Influenza A was second in frequency (164 or 7.4%) followed by PIV type 3 (129 or 5.8%) 
(Table 2). 
Seasonality of respiratory viral infections (paper I) 
We observed the largest epidemics of pneumonia during the end of the monsoon season and 
in winter, and most epidemic peaks coincided with epidemics, individual or compiled, of 
RSV, hMPV, influenza A and B, and PIV type 3. PIV type 1 occurred in an endemic pattern 
throughout the year with no major peaks. We only identified 17 cases with PIV type 2 
infection during the entire study and these were sporadic. An annual RSV epidemic peaked 
either in September (2004 and 2006) or in December (2005). We observed a single hMPV 
epidemic, which occurred in December to January the first year, while the only substantial 
PIV type 3 outbreak peaked in June 2006. Influenza epidemics were predominantly observed 
during winter months and outbreaks of type A and B infections more or less overlapped. The 
spatial-temporal distribution of the individual viruses is shown online in the following 
website: http://folk.uib.no/mihtr/CHRP/Virus.html. 
Respiratory viral infections and climatic parameters (paper I) 
In the Spearman correlation analyses RSV and hMPV were positively associated with 
relative humidity (r=0.40; P=0.015 and 0.55; P 0.0005, respectively) but not with 
temperature or rainfall. In contrast, PIV type 3 was positively associated with temperature 
(r=0.65; P<0.0001) and rainfall (r=0.68; P<0.0001) but not with humidity. Influenza A did 
not correlate with any of the tree meteorological parameters, while influenza B exhibited 
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moderate negative correlation with all three (-0.31 to -0.39, P<0.066). As RSV infections 
peaked towards the end of the monsoon in the first and third year of the study but showed no 
correlation with rainfall, we further explored if there was an association with preceding 
rainfall. By introducing a 2-month lag after peak precipitation, we did indeed observe such 
an association (r=0.49; P=0.003). 
Clinical features and outcomes of respiratory viral infections (paper II) 
RSV was identified in 298 (14.3%) of the 2,088 cases with non-severe pneumonia, 36 
(27.5%) of the 131 cases with severe pneumonia, and in 154 (15.2%) of the 1,016 infants 2-
11 months of age. Mean age did not differ much between children infected with the different 
viruses (13.4 to 15.1 months) (Table 2), but was higher in those with non-severe compared 
to those with severe illness (13.7 vs 8.6 months). Half (53%) of the severe cases occurred in 
infants 2-5 months old and nearly one third of these were infected by RSV. Among those 
infected with PIV type 3 and RSV, nearly half were 2-11 months old (48.8% and 46.1%, 
respectively). 
High fever (axillary temperature >38.5° C) was more common in those infected with 
influenza A compared to those who were not (OR 2.79; CI 1.89, 4.11). This tendency, albeit 
less pronounced, was also seen for Influenza B (1.45; CI 0.80, 2.62). A similar association 
between high fever and RSV infection was observed, but only in infants (Table 2 and 3). 
Being infected with RSV was also associated with LCI (i.e. severe pneumonia), hypoxia 
(SpO2<93%), wheezing, and crepitations. The associations between RSV infection and these 
clinical signs were more pronounced in children below 1 year of age (Table 2-4), but only 
for crepitations and hypoxia was there a significant age interaction with RSV (Table 2 and 
4). 
Among the 2,088 non-severe pneumonia cases, children infected with RSV had a higher risk 
of treatment failure and delayed time to recovery compared to children without RSV. RSV 
positive cases experienced treatment failure twice as often as the other children and had on 
average 18% longer duration of illness (Table 5). None of the total 2,219 cases of 
pneumonia died as a result of their disease. 
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CRP as exposure variable 
We also analyzed the data using high CRP as a proxy for bacterial pneumonia. We used two 
different cut-offs (>40 mg/L and >80 mg/L) to define high CRP. CRP >40 mg/L was 
associated with high fever, crepitations, and LCI (Table 3 and 4). We found that the 
associations were even more pronounced using 80 mg/L as the cut-off. Neither CRP >40 
mg/L nor CRP >80 mg/L were significantly associated with SpO2 <93%. However, using 
SpO2 <90% as the cut-off for hypoxia, having CRP >40mg/L and >80 mg/L were both 
substantially and statistically significantly associated with hypoxia, the OR being 4.0 (CI 
2.1, 7.6) and 6.0 (CI 2.4, 15.0), respectively. Similar to what was observed for RSV, the 
association between CRP and crepitations was stronger for infants than for older children. 
Wheezing was highly associated with CRP >80 mg/L, but for this outcome we observed a 
qualitative interaction; wheezing was more common in infants with high CRP than in those 
with lower CRP (OR 1.8), while the opposite was found in older children (OR 0.50). For the 
remaining clinical signs and disease outcomes there were no other significant interactions; 
the lowest P-value for interaction with LCI being 0.11 for CRP >80 mg/L in infants (OR 
4.3) versus in older children (OR 0.72) (Table 3 and 4). 
Among the non-severe pneumonia cases, CRP >40 mg/L was associated with longer episode 
duration (HR 0.88; CI 0.80, 0.97; P=0.009). High CRP was also associated with increased 
risk of treatment failure. This association was significant both for CRP >40 (OR 1.4; CI 1.1, 
1.9; P=0.012) and CRP >80 (OR 2.1; CI 2.3, 3.6; P=0.005). These associations were not 
confounded by the presence of virus. 
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Table 3. Association between RSV and CRP category and clinical signs. 
 
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 53/334 (15.9) 240/1884 (12.7) 1.45 (1.03, 2.04)
2-11 mo 27/154 (17.5) 75/861 (8.7) 2.53 (1.56, 4.12)
12-35 mo 26/180 (14.4) 165/1023 (16.1) 0.97 (0.61, 1.54)
CRP category
>40 mg/L overall 73/334 (21.9) 220/1880 (11.7) 2.23 (1.65, 3.02)
2-11 mo 26/137 (19.0) 76/874 (8.7) 2.64 (1.62, 4.31)
12-35 mo 47/197 (23.9) 114/1006 (14.3) 2.02 (1.38, 2.97)
>80 mg/L overall 29/79 (36.7) 264/2135 (12.4) 4.47 (2.75, 7.27)
2-11 mo 8/29 (27.6) 94/982 (9.6) 3.62 (1.59, 8.20)
12-35 mo 21/50 (42.0) 170/1153 (14.7) 4.98 (2.69, 9.23)
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 182/334 (54.5) 812/1885 (43.1) 1.40 (1.09, 1.80)
2-11 mo 96/154 (62.3) 393/862 (45.6) 1.80 (1.26, 2.58)
12-35 mo 86/180 (47.8) 419/1023 (41.0) 1.17 (0.85, 1.62)
CRP category
>40 mg/L overall 143/334 (42.8) 850/1881 (45.2) 0.89 (0.70, 1.13)
2-11 mo 68/137 (49.6) 420/875 (48.0) 1.04 (0.72, 1.50)
12-35 mo 75/197 (38.1) 430/1006 (42.7) 0.80 (0.58, 1.10)
>80 mg/L overall 32/79 (40.5) 961/2136 (45.0) 0.81 (0.51, 1.28)
2-11 mo 18/29 (62.1) 470/983 (47.8) 1.77 (0.82, 3.81)
12-35 mo 14/50 (28.0) 491/1153 (42.6) 0.50 (0.26, 0.94)
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 133/334 (39.8) 518/1885 (27.5) 1.71 (1.33, 2.02)
2-11 mo 62/154 (40.3) 194/862 (22.5) 2.28 (1.59, 3.27)
12-35 mo 71/180 (39.4) 324/1023 (31.7) 1.36 (0.97, 1.90)
CRP category
>40 mg/L overall 118/334 (35.3) 533/1881 (28.3) 1.39 (1.08, 1.78)
2-11 mo 53/137 (38.7) 203/875 (23.2) 2.12 (1.46, 3.09)
12-35 mo 65/197 (33.0) 330/1006 (32.8) 1.03 (0.73, 1.44)
>80 mg/L overall 35/79 (44.3) 616/2136 (28.8) 1.97 (1.23, 3.16)
2-11 mo 18/29 (62.1) 238/983 (24.2) 5.12 (2.37, 11.07)
12-35 mo 17/50 (34.0) 378/1153 (32.8) 1.10 (0.60, 2.03)
a
 Adjusted for age, breastfeeding status and treatment group. The estimates for RSV were adjusted for presence
of the other six viruses, while viral status (positive or negative) was included in the model for CRP categories.
The result of the CRP analysis was missing in four cases.
Wheeze n/N (%) 994/2,219 (44.8)
P=0.073
P=0.289
P=0.012
P=0.54
Crepitations n/N (%) 651/2219 (29.3)
P=0.036
P=0.005
P=0.002
Axillary temperature 38.5° C n/N (%) 293/2,218 (13.2)
P=0.004
P=0.40
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Table 4. Association between RSV and CRP category and clinical severity signs. 
 
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 36/334 (10.8) 95/1885 (5.0) 2.17 (1.43, 3.28)
2-11 mo 28/154 (18.2) 67/863 (7.8) 2.42 (1.50, 3.91)
12-35 mo 8/180 (4.4) 28/1022 (2.7) 1.63 (0.72, 3.72)
CRP category
>40 mg/L overall 34/334 (10.2) 97/1881 (5.2) 2.52 (1.65, 3.85)
2-11 mo 25/137 (18.3) 70/875 (8.0) 2.85 (1.73, 4.69)
12-35 mo 9/197 (4.6) 27/1006 (2.7) 1.92 (0.88, 4.20)
>80 mg/L overall 9/79 (11.4) 122/2136 (5.7) 2.68 (1.33, 5.42)
2-11 mo 8/29 (27.6) 87/983 (8.9) 4.31 (1.91, 9.72)
12-35 mo 1/50 (2.0) 35/1153 (3.0) 0.72 (0.10, 5.37)
P=0.11
Lower chest indrawing n/N (%) 131/2,219 (5.9)
P=0.41
P=0.40
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 123/334 (36.8) 547/1885 (29.0) 1.40 (1.09, 1.80)
2-11 mo 66/154 (42.9) 242/862 (28.1) 1.89 (1.32, 2.69)
12-35 mo 57/180 (31.7) 305/1023 (29.8) 1.07 (0.76, 1.52)
CRP category
>40 mg/L overall 111/334 (33.2) 557/1881 (29.6) 1.21 (0.94, 1.55)
2-11 mo 48/137 (35.0) 258/875 (29.5) 1.31 (0.90, 1.92)
12-35 mo 63/197 (32.0) 299/1006 (29.7) 1.13 (0.81, 1.58)
>80 mg/L overall 29/79 (36.7) 639/2136 (29.9) 1.38 (0.87, 2.21)
2-11 mo 13/29 (44.8) 293/983 (29.8) 1.94 (0.93, 4.07)
12-35 mo 16/50 (32.0) 346/1153 (30.0) 1.12 (0.61, 2.01)
Category
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioa  (95% CI)
P-value for 
interaction
RSV overall 11/334 (3.3) 31/1885 (1.6) 2.18 (1.05, 4.52)
2-11 mo 8/154 (5.2) 20/862 (2.3) 2.33 (1.00, 5.45)
12-35 mo 3/180 (1.7) 11/1023 (1.1) 1.88 (0.49, 7.20)
CRP category
>40 mg/L overall 15/334 (4.5) 27/1881 (1.4) 3.98 (2.08, 7.62)
2-11 mo 10/137 (7.3) 18/875 (2.1) 4.38 (1.97, 9.76)
12-35 mo 5/197 (2.5) 9/1006 (0.9) 3.33 (1.12, 9.89)
>80 mg/L overall 6/79 (7.6) 36/2136 (1.7) 6.04 (2.44, 14.96)
2-11 mo 4/29 (13.8) 24/983 (2.4) 7.02 (2.22, 22.13)
12-35 mo 2/50 (4.0) 12/1153 (1.0) 4.69 (1.00, 21.97)
a
 Adjusted for age, breastfeeding status and treatment group. The estimates for RSV were adjusted for presence
of the other six viruses, while viral status (positive or negative) was included in the model for CRP categories.
The result of the CRP analysis was missing in four cases.
P=0.79
P=0.69
P=0.69
Oxygen saturation <93% n/N (%) 670/2,219 (30.2)
P=0.024
P=0.56
P=0.26
Oxygen saturation <90% n/N (%) 42/2,219 (1.9)
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Table 5. Association between RSV and CRP category and outcomes of non-severe pneumonia episodes. 
 
No. of 
infections
Positive       
n/N (%)
Negative          
n/N (%)
Odds ratioc  (95% CI)
P-value for 
interaction
RSV overall 100/296 (33.8) 366/1774 (20.6) 2.01 (1.52, 2.65)
2-11 mo 50/125 (40.0) 172/788 (21.8) 2.4 (1.62, 3.61)
12-35 mo 50/171 (29.2) 194/986 (19.7) 1.76 (1.21, 2.56)
CRP category
>40 mg/L overall 80/298 (26.9) 386/1768 (21.8) 1.44 (1.08, 1.91)
2-11 mo 31/112 (27.7) 191/797 (24.0) 1.33 (0.85, 2.07)
12-35 mo 49/186 (26.3) 195/971 (20.1) 1.51 (1.04, 2.19)
>80 mg/L overall 24/69 (34.8) 442/1997 (22.1) 2.11 (1.25, 3.55)
2-11 mo 8/21 (38.1) 214/888 (24.1) 2.10 (0.86, 5.13)
12-35 mo 16/48 (33.3) 228/1109 (20.6) 2.06 (1.07, 3.97)
No. of 
infections
Positive 
Median (IQR)
Negative        
Median (IQR)
Hazard 
ratioc      
(95% CI)
P-value for 
interaction
RSV overall 3 (2-5) 2 (1-4) 0.82 (0.75, 0.90)
2-11 mo 3 (2-5) 2 (1-4) 0.85 (0.75, 0.96)
12-35 mo 3 (2-4) 2 (1-4) 0.79 (0.69, 0.89)
CRP category
>40 mg/L overall 3 (1-5) 2 (1-4) 0.88 (0.80, 0.97)
2-11 mo 3 (1-5) 2 (1-4) 0.85 (0.73, 0.99)
12-35 mo 2.5 (1-4) 2 (1-4) 0.89 (0.79, 1.02)
>80 mg/L overall 3 (2-5) 2 (1-4) 0.84 (0.70, 1.01)
2-11 mo 3 (2-5) 2 (1-4) 0.91 (0.71, 1.16)
12-35 mo 3 (2-4.5) 2 (1-4) 0.83 (0.66, 1.04)
a Treatment failure defined as change in antibiotic or hospitalization for pneumonia within the first three days.
b
 The data was analyzed using Cox proportional hazards regression models. Recovery day was defined as the
 first of  two consecutive days with a return of respiratory rate to normal range for age.
c
 Adjusted for age, breastfeeding status and treatment group. The estimates for RSV were adjusted for presence
The result of the CRP analysis was missing in four cases.
 of the other six viruses, while viral status (positive or negative) was included in the model for CRP categories.
Treatment failurean/N (%) 466/2,070 (22.5)
Category
P=0.245
P=0.662
P=0.970
P=0.597
Time to recovery from pneumoniab N=2,088
Category
P=0.412
P=0.578
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Matching (paper III) 
We approached 1,955 potential control children for the 726 pneumonia cases enrolled in the 
case-control study. For 60% of the cases, we approached 1-2 potential controls, while for the 
remaining 40%, three or more children were asked to participate before we could select an 
eligible control (Figure 4). The most common reasons for not being selected as a control 
were that the family were travelling or had moved, in addition to not bringing the child to the 
clinic for evaluation of eligibility despite having agreed to do so (Figure 5). We included 
75% of the controls within the first week of having included the corresponding case, 90% 
within two weeks and 98% within three weeks (Figure 6). For two pairs, the case and control 
were included 33 and 37 days apart. In 20 cases, no control was obtained within an 
acceptable time. 
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Figure 4. Number of potential controls approached for cases. 
The presented results are based on the analyses of 680 matched cases-control pairs (Figure 
5). Despite that the age matching was done according to protocol (month and year of birth), 
the age of the case and the control differed by 2 months in ten pairs. This was a result of age 
being calculated as age in completed months, not age in days, combined with some delay in 
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enrolment of the controls as compared to the corresponding cases. We used the age of the 
case (in completed months) when stratifying the analysis according to age group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Flow chart of control selection and matching. *Other reasons were mainly previous or current 
enrolment in one of the studies. 
Association between respiratory viral infections and pneumonia (paper 
III)  
We detected at least one virus in 248 (36.5%) of the cases and 48 (7.1%) of the controls. In 
the conditional logistic regression analyses, we found that all the seven viruses were 
associated with pneumonia; the matched odds ratios (MORs) for the individual viruses 
ranging from 2.0 to 13.0. The viruses most strongly associated with pneumonia were PIV 
type 3, RSV and influenza A, with MORs of 13.0, 10.7 and 6.3, respectively. PIV type 3 and 
Travelling: 301
Moved: 240
Antibiotics last 48 hours: 94
Died: 10
Dysentery: 7
Other reason*: 165
Did not come for inclusion: 258
No consent: 154
Missing information
NPA could not be obtained:3 2 1
Inhibition of PCR: 15 10 5
Respiratory rate not recorded: 3 0 3
Protocol deviation
Not age matched: 5 5 0
1,955 potential controls 
approached
Reason for not being selected
706 included 
controls
680 matched case-control pairs included 
in the analyses
726 included 
cases
No eligible control within 
reasonable time: 20
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RSV were the most prevalent viruses in this case-control study, while influenza A was the 
second most detected virus after RSV in the three-year cross-sectional study. The proportion 
of the individual viruses in the controls ranged from 0.4% to 1.8%, whereas these 
proportions were even lower in the controls without any respiratory symptoms and ranged 
from 0% to 1.1%. 
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Figure 6. Time lag from inclusion of case to the inclusion of the matched control. 
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5. Discussion 
Frequency of respiratory viral infections 
The etiology of viral childhood pneumonias have been studied extensively during the last 3-
4 decades and there is a large body of research contributing to this field both in 
industrialized countries as well as in LMICs. Comparing studies is difficult because 
pneumonia case definitions, study settings and method of case ascertainment, as well as age 
group of the study populations differ. Many hospital-based studies have had limited 
observation time, and some were performed during one or only a few seasons (105, 182-
184). Hospital-based studies will tend to include cases with more severe illness compared 
with longitudinal community-based studies. In addition, various clinical specimens and 
diagnostic assays with different sensitivity and specificity have been used in order to identify 
a varying number of viral agents (185-189). Finally, a number of newly identified viruses 
have recently emerged as pathogens with the potential to cause pneumonia (161, 162, 190-
192). This has contributed to great variations in the reported overall frequency of viruses 
detected in children with pneumonia. 
We identified at least one respiratory RNA virus in 40% of the pneumonia cases. Studies of 
viral etiology of ALRI in tropical and developing countries published up to 1996 identified 
virus in 9% to 64% of hospital-based studies and 11% to 36% of community-based studies 
(39). Notably, measles played a major role in some of the studies undertaken up to the mid 
1980s. Importantly, studies before 1980 mainly depended on classical diagnostic techniques 
such as culture and serology for viral identification. Rapid antigen tests, such as 
immunofluorescence (IF) and enzyme-linked immunosorbent assay (ELISA), were more 
widely used in later studies, IF often in combination with culture (39). The rapid antigen 
tests were more sensitive than culture for RSV (193, 194) but less sensitive for some of the 
other common respiratory viruses, in particular adenovirus (195, 196). 
The epidemiological setting of our study could be compared to two rather large studies in 
Pakistan and Thailand that included both ambulant and admitted under-5s with ALRI, albeit 
over a period of only 17 and 12 months, respectively. The study in Pakistan detected virus in 
37% of cases using viral culture and IF, while the study in Thailand identified virus in 45% 
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using the same methods in addition to serology (188, 189). In addition to the viruses we 
detected, these studies also identified adenovirus, and the study in Thailand identified 
another four additional respiratory viruses. Two recently published community-based studies 
reported comparable results; a cohort study of children followed till 24 months of age in 
Bangladesh detected virus in 45% of ALRI cases (197), while a study in India that followed 
children up till 42 months of age identified virus in 26% of ALRI cases (35). Both studies 
identified adenovirus in addition to the viruses included in our assay using antigen detection 
and the latter also performed rapid culture assay for RSV. 
There are few comprehensive studies of common respiratory viruses from LMICs that have 
employed sensitive molecular methods for virus identification (55). A study in Brazil 
detected a virus in 60% of hospitalized under-5s with radiologically diagnosed pneumonia 
using PCR for rhinovirus and serology and antigen tests for 7 other common respiratory 
viruses (187). A study of hospitalized under-5s conducted over 14 months in Vietnam 
detected viruses using multiplex PCR for 13 organisms in 70% of ALRI cases, notably with 
a high proportion of rhinovirus (55). A similar 5-year study in Korea, which is a 
industrialized country in Asia, reported identification of virus in 60% of ALRI cases (191).  
Frequency of RSV 
RSV has been the predominating virus in the great majority of etiology studies in LMICs 
(39). We identified RSV in 15.1% (CI 13.6%, 16.6%) of all pneumonia cases (14% [CI 
12.8% to 15.8%] of non-severe cases and 27% [CI 20% to 36%] of severe cases) over three 
years and three RSV epidemics. In comparison, a community-based study that followed 635 
Kenyan children from birth until all had experienced three RSV epidemics identified RSV 
using IF in 13% of those with ALRI, 19% of severe ALRI cases and 5 % of hospitalized 
ALRI cases (36).  
However, the proportion of RSV positive specimens in children with ALRI varies greatly 
between studies (39). Even studies of under-5s in four LMICs based on a standardized WHO 
protocol using antigen detection (ELISA) found the proportions of ALRI and severe ALRI 
with RSV to be 18% to 35% and 7% to 45%, respectively (34). In a comprehensive review, 
Stensballe and co-workers estimated the proportion of RSV positive tests in children with 
ALRI at a median of 20% (5
th
 to 95
th
 percentile 1 to 53) in LMICs and 25% (5
th
 to 95
th
 
percentile 1 to 75) in industrialized countries (37). They reported the proportion of RSV 
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positive samples in studies performed before 1979 and after 1980 at a median of 17% and 
23%, respectively, and in field studies and hospital-based studies at a median of 15% and 
21%, respectively. From 1980 onwards, rapid antigen tests that were more sensitive for RSV 
became available. In the PCR era, the data on the proportion of RSV positive tests in 
children with ALRI in LMICs derive mostly from hospital-based studies. Two studies in 
India and Vietnam employing multiplex PCR identified RSV in 20% of 301 and 22% of 557 
under-5s with ALRI, respectively (54, 55), the former study spanning 2 years and the latter 
14 months. These results are similar to findings in under-5s in industrialized countries (51, 
191).  
We detected RSV somewhat less frequently than in the study in India (54) and in Vietnam 
(55). The reasons for this could be differences in study design and setting, pneumonia 
definition, validity of the diagnostic assays and age groups. While our study included mainly 
(94%) non-severe pneumonia visiting a field clinic, the Indian study included almost equal 
proportions of inpatients and outpatients; the Vietnamese study only inpatients. Both studies 
included children up to five years of age. Our study encompassed children 2-35 months, and 
the fact that we did not include cases <2 months of age, who also face a considerable RSV 
burden (36), could also have contributed to this difference. This could possibly also explain 
why the proportion of RSV was not higher in infants than in toddlers in our study. Studies of 
infants typically report higher proportions of RSV compared to older children (34). 
For five days during the RSV epidemic that peaked in September 2004 we were unable to 
collect NPA from 25 pneumonia cases due to lack of collection equipment. These cases were 
consequently not included in the virus study, but because of their modest number they could 
only have had a slight impact on the final proportion of RSV in the study. Even in the 
extreme situation of all of these cases having RSV infection, including them would have 
increased our proportion with only 1 percentage point. 
Frequency of influenza, parainfluenza and human metapneumovirus 
In the current study, influenza A (7.4%) was second in frequency after RSV followed by 
PIV type 3 (5.8%), PIV type 1 (4.4%), hMPV (4.2%) and influenza B (3.8%). The 
longitudinal study of children followed from birth until 42 months in rural India detected 
influenza A in 6.6% of ALRI cases and PIV type 3 in 9% using IF and rapid culture (35) 
(and personal communication Shobha Broor, AIIMS, New Delhi). Comparing our results 
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with those of the two hospital-based studies using multiplex PCR in Vietnam (55) and India 
(54) mentioned above, we identified influenza A less frequently than in Vietnam (16.7%) 
and more frequently than in India (3%), while both studies identified none or very few cases 
of influenza B. Proportions of samples positive for PIV type 3 and hMPV were very similar 
to our findings. The proportion of hMPV positive specimens in the current study is also 
comparable with the results from studies of hospitalized children <6 years of age in Hong 
Kong (hMPV positive 5.5%) (49) and <3 years of age in Mexico (hMPV positive 6.1%) 
(56); both studies lasted more than one full year. In contrast, a three-year study in South 
Africa detected hMPV in as much as 11% of HIV-uninfected children <4 years old 
hospitalized for ALRI (48). No community-based studies of hMPV pneumonia in LMICs 
covering at least one year could be found for comparison with our data. A community study 
of febrile children <13 years of age detected hMPV by serologic testing in 8 of the 20 
pneumonia cases identified over a year (58). 
Undiagnosed infections 
We did not identify any virus in 60% of the pneumonia cases included in the three-
year study (paper I). The proportion of cases that tested positive for virus varied 
greatly from month to month, ranging from 2.3% (November 2006) to 84.5% 
(September 2004). Our ability to detect a viral pathogen was highest when there was 
most pneumonia, which could indicate that the pneumonia epidemics we observed to 
some extent were driven by viral infections. We could have failed to identify some 
cases who were actually infected with the viruses included in our PCR assay. 
However, studies identifying a wider array of viral agents than the 7 seven targeted 
by our Hexaplex Plus assay, identified virus in up to 70% of pneumonia cases (55). 
Thus, viruses not included in our assay, as well as bacteria, will have caused many of 
the undiagnosed infections. In fact, bacteria could also be present in the cases were 
we did detect a virus. Viral-bacterial mixed infections are known to be common in 
childhood pneumonia (185). Numerous clinical and experimental studies indicate that 
infections with respiratory viruses, in particular influenza, predispose individuals to 
bacterial superinfection (198). Vaccine studies have shown that influenza vaccination 
reduces the incidence of bacterial respiratory infections (198) and immunization with 
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a 9-valent pneumococcal conjugate vaccine prevented pneumonia hospitalizations 
associated with respiratory virus in children (199). 
Seasonality of respiratory viral infections 
RSV 
Our study spanned over three years, which, despite being of longer duration than most other 
studies, is a short time period to draw any conclusions regarding seasonality patterns of the 
different viral infections. However, we observed three annual outbreaks of RSV infections. 
In 2004 and 2006, the RSV epidemics peaked in September, i.e. in relation to the rainy 
season, while in 2005 the epidemic peaked in December, and this peak was smaller 
compared to the two other years. Interestingly, RSV activity was completely absent for 3-6 
months between epidemics. Similarly, in Dhaka epidemic peaks of RSV infection were seen 
both in relation to the monsoon and the cold season, but in contrast to our findings, RSV 
activity was evident almost throughout the year (200). RSV epidemics in relation to the wet 
season have previously been reported from other locations on the Indian subcontinent (201, 
202). There are also descriptions of outbreaks during cold but also rainy winter months in 
Pakistan (188). Similar associations with rainfall are reported for RSV in a number of 
tropical locations (203). 
Association with meteorological parameters 
RSV activity in a community is influenced by transmission conditions, which may be 
influenced by changes in climate (204). Investigating possible correlation between monthly 
number of RSV cases and meteorological variables, we found that RSV infections were 
positively associated with relative humidity, a finding that also has been reported from 
tropical climates (205, 206). This is in contrast to most temperate locations where RSV 
infections are inversely correlated with temperature and not with humidity. One study in 
temperate Argentina reported RSV frequency to correlate positively with relative humidity, 
like ours, and inversely with temperature (207). Even though two of the three observed RSV 
epidemics in the current study occurred in relation to the rainy season, we found no 
correlation between monthly frequency of RSV and monthly rainfall. By introducing a two-
month lag after peak precipitation we did identify such an association (data not shown), 
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which is, however, likely to be influenced by other unknown factors. Due to the epidemic 
nature of the viral infections under study, observations based on monthly number of episodes 
are correlated. Therefore, the precision of the observed correlations is overestimated. Further 
studies are required to examine the degree to which the observed associations between viral 
infections and meteorological factors are actually caused by clustering of individual 
infections over limited time periods. 
Climatic parameters are likely to be interrelated, which may obscure conclusions drawn 
from the univariable analyses employed by us. Moreover, RSV activity has been shown to 
relate to temperature in a bimodal fashion (204), i.e. the number of RSV cases increased 
when the mean temperature was in the range of 2-6°C and then again when the temperature 
was above 24-30°C. We observed that rainfall and temperature were strongly correlated, 
while relative humidity was not correlated with any of the two other variables (data not 
shown). Under controlled experimental conditions, both temperature and humidity have an 
impact on survival of RSV in aerosols (204), but if this is important in the transmission 
between humans is not known. Moreover, seasonal changes in social behavior may modify 
associations with climatic factors. Indoor crowding, which occurs during cold months in 
temperate climates and during the rainy season in tropical climates, is a known risk factor for 
RSV infection (85). The relationship between climate and virus activity may be subject to a 
number of other unknown confounding factors. 
Interference 
Interference of other viruses, i.e. that major respiratory viruses (and possibly other common 
epidemic viruses) do not reach their epidemic peak at the same time (208, 209), could be 
another possible determinant for timing and magnitude of an outbreak with RSV. A recent 
example of such possible interference between respiratory viruses was observed in 
Scandinavia during the autumn of 2009 when rhinovirus seemed to interrupt the spread of 
swine flu and delayed the outbreak until later in the winter (210). In fact, the pneumonia 
outbreak during winter 2005/2006 in the current study was compiled by RSV and influenza 
(both type A and B). During influenza infection, infected cells produce interferon and other 
cytokines, which causes the cells to enter an antiviral state (210). Thus, spread of influenza 
in the community may have limited the spread of other viruses, in this case RSV. 
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Biennial epidemic pattern 
Although the most typical pattern of RSV infections in temperate locations is regular annual 
epidemics during the cold season, there are also reports of alternating cycles of large and 
small annual epidemics with different timing of the peak activity in several European 
countries (59, 211-213). The reasons for such dual rhythm of biennially alternating large 
winter peaks and smaller spring peaks are unknown, but climatic factors, alternating 
dominating subtypes and interference of other viruses have been suggested (59, 212, 213). 
We have too short observation time to determine if the observed RSV epidemics fit into a 
similar biennial pattern. 
Parainfluenza virus 
PIV type 1 activity was endemic with no major peaks throughout the study period, which 
deviates from the pattern of biennial autumn epidemics frequently described elsewhere (66, 
71). We observed only a single, not yearly, outbreak of PIV type 3, but the timing/season of 
the epidemic was in line with what has been reported in temperate (66) and subtropical 
regions (72). The PIV type 3 epidemic occurred in spring 2006 after the termination of the 
influenza epidemic, a phenomenon also observed over 6 consecutive years in the US (97). 
We also saw clusters of PIV type 3 infection at the same time of the year during the previous 
and the following year that did not reach epidemic proportions. PIV type 3 predominated 
during the wet and warm summer months in the current study. In tropical locations, such as 
Singapore and Papua New Guinea, PIV type 3 infections have also been described as 
endemic with annual epidemics occurring during the first half of the year and occasionally in 
autumn (71, 214). 
Influenza virus 
We found that peaks of influenza infections were greatest during winter months with 
overlapping activity of type A and B. We detected influenza in 25 of the 36 months of the 
study, and our findings are in line with those from tropical and sub-tropical locations where 
influenza is diagnosed greater parts of the year (215, 216). There are several reports from 
tropical areas of influenza epidemics occurring during the rainy season (203). We, however, 
only observed moderate activity during the months of rain. A summer outbreak of influenza 
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has been described in the plains of southern Nepal (217), where the climate is different from 
that in the hill region. 
Human metapneumovirus 
The single hMPV winter epidemic seen in the current study peaked in January 2005 after a 
major RSV epidemic. A winter outbreak of hMPV is consistent with observations in Europe 
(44) and South Africa (48). In India (54) and Bangladesh (58) hMPV peaks occurred in 
March and April, which is the dry but warm pre-monsoon season. The incidence of hMPV 
has previously been reported to vary substantially from year to year (62). There is a lack of 
studies with surveillance of several years’ duration in LMICs. Studies with longer 
observation time, primarily in Europe, have reported a biennial pattern of alternating early 
and late occurrence of epidemics (59, 63, 64, 218); similar to what has been reported for 
RSV. Moreover, in these studies hMPV epidemics occurred anti-cyclical to RSV, i.e. small 
hMPV epidemics occurred in years with large RSV epidemics, and vice versa, an 
observation that supports the concept of interference by competing pathogens. 
Association between etiology and clinical signs and 
outcomes of infection 
Children with RSV infection were twice as likely to present with severe pneumonia (i.e. 
LCI) or SpO2 <90% compared to the other children. Apart from influenza B that also was 
associated with LCI, none of the other viruses were associated with any of these severity 
signs. It is known that RSV involves the lower airways more frequently than other common 
respiratory viruses (67). Among children with RSV infection, we also noted that several 
clinical signs were more common or only observed in infants.  
Similar to RSV, high CRP (used as an indirect marker of suspected bacterial pneumonia) 
was associated with LCI, crepitations), high fever and SpO2 <90%. The associations were 
most pronounced using a cut-off for CRP of 80 mg/L and for infants, but the age interaction 
for these clinical signs was only significant for crepitations and high fever. These findings 
are plausible, as severe presentation of pneumonia is more common in infancy. Although 
CRP has generally low sensitivity and specificity in differentiating between bacterial and 
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viral pneumonia, a CRP concentration >80 mg/L has been shown to predict bacterial 
pneumonia well (specificity 0.90) in children <2 years of age (133). 
Among the 2,088 non-severe cases, longer duration of illness and increased risk of treatment 
failure was observed for cases with RSV and for cases with high CRP. A high CRP would 
usually indicate a more severe infection that could take longer than three days to resolve 
despite effective antibiotic treatment. Moreover, antimicrobial resistance to cotrimoxazole 
(the first line antibiotic used) is common in Nepal (138). The antibiotic treatment would 
have no impact on a viral infection unless there is a concomitant bacterial infection. The 
observation that RSV was associated with treatment failure probably reflects that RSV 
infections took longer to resolve than the other infections, which may have tended to resolve 
spontaneously within 3 days of treatment. 
Although the assumed bacterial pneumonia cases more frequently presented with a higher 
degree of hypoxia (SpO2<90%) compared with the RSV cases, our findings suggest that the 
presentation and outcome of RSV infections was on the whole similar to that of assumed 
bacterial infection, underscoring the paramount position of RSV among the respiratory 
pathogens. Although we cannot rule out the possibility of a concomitant bacterial infection, 
adjusting for high CRP in the analyses did not change the estimates for RSV or the other 
viruses (data not shown). Most previous studies demonstrating the severity of RSV 
infections with regard to clinical presentation and outcome are from hospitalized children 
(83, 186, 219). The current findings indicate that a sizable proportion of children with RSV 
infections exhibit signs of severe illness also in a community setting with predominantly 
ambulant patients. In the United States, the outpatient load of RSV infection is 10-25 times 
higher than the inpatient load for children <5 years (29). If this is the case also in Nepal and 
other LMICs, the burden of ALRI caused by RSV is high. 
Association between respiratory viral infections and 
pneumonia 
PIV type 3, RSV, Influenza A, PIV type 1, hMPV and Influenza B were all significantly 
associated with pneumonia, with matched odds ratios ranging from 13.0 to 2.2. We detected 
PIV type 3, RSV, and Influenza A in 14%, 10% and 3% of cases, while the corresponding 
proportions in the controls were 1.8%, 1.2% and 0.6%, respectively. According to a recent 
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review, RSV positive specimens have been identified using PCR in 0% to 5% of 
asymptomatic children (159). For other common viruses such as PIV, influenza and hMPV, 
proportions have ranged from 0% to 2% (51, 159). Similar results have been reported from 
previous studies in LMICs using culture, IF or serology (10, 214). These viruses are not 
frequently present in control children, which is an indicator of their causal role in pneumonia 
when detected from the upper airways during illness. PIV type 2 had a matched odds ratio of 
2.0, and was the most infrequent of the viruses with only 9 infections during the entire case-
control study. Accordingly, the corresponding precision was lower than for the other viruses; 
its 95% confidence interval spanning 0.5 to 8.0. Our findings are in line with those reported 
for Australian children during the first year of life (220). We were not able to identify 
reports on such associations from other LMICs. 
The viruses most strongly associated with pneumonia in the case-control study (paper III) 
were also the most prevalent viruses detected in pneumonia cases in this community during 
the three-year cross-sectional study (paper I). Because the studies were clinic-based, these 
two observations will necessarily be closely related. It is likely that the most pathogenic 
viruses give disease that prompts visits to a health facility. A cohort study with frequent 
sampling of children in the homes may have given somewhat different estimates for the 
viruses. However, our estimates are consistent with those obtained in such a longitudinal 
study (220).  
We identified at least one virus in 7.1% of controls. As for cases, the overall proportion of 
viruses detected in controls will depend upon the number and kind of agents tested for. Viral 
pathogens or atypical bacteria have been found in up to 68% of control subjects less than 5 
years in Netherlands, but the study employed a broader diagnostic panel than ours and the 
major agents detected (for all age groups) were rhinovirus, coronavirus and Chlamydophila 
species (160). The availability of PCR for rhinovirus has increased the proportion of positive 
findings in asymptomatic subjects (159). In the Netherlands, rhinovirus has been detected in 
22% of children aged up to 7 years by biweekly sampling (221) and 20% of asymptomatic 
children aged up to two years (222). Studies on some newly identified viruses such as hBoV 
and hMPV are mainly based on PCR detection. In Israeli children, hMPV was identified in 
2.2% of season-matched controls (51), while hBoV was detected in 8.6% of asymptomatic 
infants in a Danish birth cohort followed for 1 year with monthly sampling (223), but none 
of 68 healthy children <5 years of age in France (224, 225). Studies including PCR assays 
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for rhinovirus and hBoV tend to report higher proportions of overall virus positive 
specimens in sick children (55, 161, 162, 185, 191, 221), but these viruses are also among 
the viruses detected as frequently in asymptomatic controls as in cases (221, 223). 
Quantization of viral load has been suggested in the assessment of their role in lower 
respiratory tract infection (161, 226, 227). There are no reports so far from LMICs on 
frequency of detection in controls using PCR for these viruses. 
We found a higher association between PIV type 3 and pneumonia for children six months 
and older compared with 2-5 months old children. A similar, albeit statistically non-
significant, age-dependent difference was also found for RSV. The explanation for this 
difference between infants and older children is uncertain, but could partly be due to 
maternal antibodies protecting the infants during the first 6 months of life (228-230).  
Limitations of the study 
As we did not know the exact number of children in the target age group in this population, 
we were not able to estimate true incidence rates of pneumonia and consequently not disease 
burden in the community. Our clinic was not the sole health facility in Bhaktapur, and we 
conducted an active monthly surveillance of an open cohort of children below three years of 
age and have reasons to believe that the majority of pneumonia cases were brought to our 
clinic. The proportion of severe cases (5.9%, CI 5% to 7%) was only slightly lower than the 
estimated average of 8.7% (IQR 7% to 13%) (3). Some children with severe illness were 
probably transported directly to a tertiary level hospital in the capital and thereby bypassed 
our clinic. Moreover, we excluded cases of pneumonia that had received antibiotics within 
the last 48 hours prior to inclusion. This would lead to a bias toward inclusion of milder 
cases. In fact, among those that met our inclusion criteria we found that cases with severe 
pneumonia were more likely to have received antibiotic treatment in the previous 48 hours 
compared with non-severe cases (19% vs 8%, respectively), which would result in 
underestimation of viruses that cause severe pneumonia. 
Although fieldworkers referred children with respiratory symptoms, the inclusion of cases 
for the studies relied on parents actually bringing their child to the project clinic. The 
baseline census and the subsequent active surveillance of children below three years of age 
in all the neighborhoods of Bhaktapur municipality made the project well known and the 
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free treatment offered by our study clinic for common childhood illnesses encouraged 
parents to use this facility. One could argue that this could motivate the poorer part of the 
population to utilize our services and bias the study population towards a lower socio-
economic level. However, the socio-economic features of the study population did not differ 
from those of the surveilled population (data not shown). We therefore have no reason to 
believe that there was any substantial selection bias in the inclusion of cases for the studies. 
The controls in paper III were randomly selected from a list of children under surveillance. 
Children from migrant families could in theory be underrepresented on this list and any 
difference in socioeconomic status between migrant families and the indigenous population 
could have introduced a bias in our pathogenicity odds ratio estimates. We observed a 
difference in anthropometric measures between the cases and the controls, as well as in the 
proportion of children who were delivered in hospital. Adjusting for these factors in the 
unconditional logistic regression analyses did not, however, substantially alter the estimates 
(data not shown), making such selection an unlikely source of bias. 
The political instability during the democracy movement in the spring of 2006 led to several 
days of nationwide general strike in the beginning of April. Due to the demonstrations in 
Kathmandu the government imposed daytime curfew, which failed to curb the protests. In 
the following days crowds of several hundred thousands participated in the demonstrations 
against King Gyanendra and his government and violent clashes with armed police took 
place in the streets. This culminated on April 21,
 
when the king announced that he would 
step down from power and called for general elections. Bhaktapur was less affected by the 
emergency measures and our field activities were not interrupted despite that public 
transportation in the valley came to a halt during these weeks. Our field clinic was within 
walking distance from most parts of the municipality and disruption of public transport 
should not have had a major impact on people’s ability to access the clinic. Yet the general 
political situation and emergency measures in April 2006 may have impeded parents from 
seeking medical treatment for their sick children. Notably, the inclusion of cases during 
April that year was the lowest during the whole study period and approximately half of the 
inclusions for April the other two years. If this can be attributed to the political situation or 
to a period of genuinely low pneumonia incidence is uncertain. 
The aim of the WHO pneumonia definition has been to ensure high sensitivity and 
simultaneously attempting to maintain adequate specificity in order to avoid failing to treat 
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bacterial pneumonia and minimize the number of children with non-bacterial pneumonia 
receiving unnecessary antibiotics. Prior to revision in 2008 (176), the WHO ARI algorithm 
detected about 80% of the children that required antibiotic treatment (231, 232). However, 
20-30% of children who met the criteria were unnecessarily treated with antibiotics, and 
many of these children presented with wheeze (232). Most children with non-recurrent 
wheeze are likely to have a viral infection and hence will not benefit from the use of 
antibiotics (232). Thus, to improve the specificity of the criteria, revised guidelines 
recommended a trial of rapid acting bronchodilator in children with wheeze and fast 
breathing and/or lower chest indrawing before being classified as pneumonia (176). In the 
current study, we treated all wheezing children with salbutamol, which is according to the 
revised 2008 guidelines, and excluded the child if he or she no longer fulfilled the criteria for 
pneumonia at reassessment. However, despite of the relatively low specificity of the WHO 
definition of pneumonia and that we allowed controls to have respiratory symptoms, we did 
demonstrate a very strong association between the presence of virus in NPA and WHO 
defined pneumonia. Any lack of specificity in diagnostic criteria for measuring study 
outcomes tends to bias the odds ratio towards 1 (233), thus, our estimates of association are 
rather under- than overestimated. 
We used a commercially available multiplex PCR kit for our analyses undertaken in Nepal. 
This assay detects the most common viruses causing pneumonia in children and has proven 
highly sensitive and specific for this purpose (166) compared to conventional methods (157, 
158). Drawbacks of the assay are that it is both costly and relatively labor intensive. We 
estimated the reagent cost per sample to approximately 50 USD and this makes it not 
feasible for routine diagnostics in a low-income country. Development of new or 
establishment of existing in-house PCR assays could increase sustainability in a LMIC 
setting, if adequate training and infrastructure is ensured. Efforts in laboratory diagnostics of 
respiratory viruses should perhaps focus on epidemiologic surveillance rather than clinical 
routine analysis, as a positive PCR test has limited implications for the individual patient, i.e. 
it does not rule out the presence of bacterial agents. 
Sensitivity of PCR analyses 
Even though we primarily included new cases of pneumonia and most cases presented early 
in the course of illness (95% within 7 days of illness), some specimen collected from cases 
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will not contain detectable viral RNA. This could be due to timing of specimen collection in 
relation to onset of symptoms, inadequate collection procedures, or loss or degradation of 
RNA during transport, processing or storage. Using a multiplex PCR implies some loss in 
sensitivity compared to PCR assays for single agents, but an advantage is the possibility of 
co-detections in a single specimen. However, the detection of more than one virus was 
relatively low, at 3.3%, in our study. 
Three-hundred-and-twenty four of the 2,219 NPAs were stored for up to 16 months at 2-8°C. 
The samples refrigerated beyond three months that yielded a negative result (n=133) were 
reanalyzed in the laboratory at the University Hospital of North Norway in Tromsø using the 
aliquot that was frozen at -70°C immediately after processing in Nepal, while positive 
samples (n=191) were not. Thus, we were probably unable to identify some co-detections 
among the positive samples that were not reanalyzed. Assuming a proportion of viral co-
infections similar to what we observed in the rest of the study, the estimated co-detection 
would have been 4.1% instead of the currently reported 3.3%. Moreover, the comparative 
study described under the “Methods” section showed that refrigeration at 2-8°C for up to 
three months resulted in a 7% loss in sensitivity compared to storage at -70°C. However, this 
concerned approximately 10% (243/2,219) of our samples only, but indicates that the 
proportion of children that tested positive for any virus could be slightly underestimated in 
the current study. 
Other pathogens 
The detection of other respiratory pathogens, notably S. pneumonia, H. influenzae and S. 
aureus, would also have been of great interest, but was not feasible within our project 
setting. In particular in the case-control study, detection of rhinovirus, adenovirus, hBoV, 
coronavirus, and enterovirus, viruses that are also frequently identified in healthy children 
(159), would have enabled us to estimate individual pathogenicity odds ratios for each virus 
and thereby better define their role in childhood pneumonia. 
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6. Conclusions 
The studies presented in this thesis show the importance of RSV, PIV type 3, and influenza 
virus in childhood pneumonia in this Nepalese community. The cross-sectional study 
contributed information on seasonal patterns and clinical features of the different viral 
infections. The observed pneumonia epidemics were to a considerable extent driven by viral 
epidemics. RSV was found to be the most common among the seven viruses identified over 
the period of three years. Annual epidemics with RSV occurred in relation to the rainy 
season or during the cold months. The newly identified virus, hMPV, was shown to circulate 
in the community and an outbreak with hMPV occurred one of the winter seasons. RSV 
infection was associated with the most severe clinical presentation and outcome among all 
the viral infections we identified. The high pathogenicity estimates for the commonly 
occurring PIV type 3, RSV and influenza viruses make them important targets for preventive 
measures, such as vaccination.  
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7. Research challenges 
The important role of RSV in community-acquired pneumonia both with regards to 
frequency and severity in young children underscore the need for continued effort to develop 
of a safe and effective RSV vaccine, as this could substantially reduce the burden of 
pneumonia in children of LMICs. 
Population-based studies should be undertaken in order to define the proportion of 
pneumonia cases attributable to each virus and to estimate the disease burden of the most 
important viral agents. 
Efforts should be made to gain better regional data on the viral and bacterial causes of 
childhood pneumonia. New viral respiratory pathogens have emerged and their exact causal 
role in pneumonia needs further investigation. 
Local epidemiologic surveillance of respiratory viruses causing pneumonia in children 
should be undertaken to enable prediction of outbreaks and for planning of preventive and 
therapeutic control measures. 
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